<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Commun Signal</journal-id><journal-id journal-id-type="iso-abbrev">Cell Commun Signal</journal-id><journal-title-group><journal-title>Cell Communication and Signaling : CCS</journal-title></journal-title-group><issn pub-type="epub">1478-811X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863771</article-id><article-id pub-id-type="publisher-id">2099</article-id><article-id pub-id-type="doi">10.1186/s12964-025-02099-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Regulation of CXCR4 function by S1P<sub>1</sub> through heteromerization</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyun-Tae</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jeong</surname><given-names>Jae-Yeon</given-names></name><address><email>jeongjy@gpcr.co.kr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huh</surname><given-names>Won-Ki</given-names></name><address><email>wkh@snu.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h9pn542</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution>School of Biological Sciences, </institution><institution>Seoul National University, </institution></institution-wrap>Seoul, 08826 Republic of Korea </aff><aff id="Aff2"><label>2</label>GPCR Therapeutics Inc, Gwanak-gu, Seoul, 08790 Republic of Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h9pn542</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution>Institute of Microbiology, </institution><institution>Seoul National University, </institution></institution-wrap>Seoul, 08826 Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>111</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>9</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The trafficking of immune cells between lymphoid organs and circulation depends on gradients of CXCL12 and sphingosine-1-phosphate (S1P), mediated through their cognate receptors C-X-C chemokine receptor type 4 (CXCR4) and S1P receptor type 1 (S1P<sub>1</sub>). S1P<sub>1</sub> facilitates the egress of hematopoietic stem cells and lymphocytes by counteracting CXCR4-mediated retention signals. However, the molecular mechanisms underlying this interplay remain poorly understood. In this study, we uncover CXCR4-S1P<sub>1</sub> heteromerization and explore their functional interactions.</p></sec><sec><title>Methods</title><p id="Par2">Bimolecular fluorescence complementation (BiFC) assay, proximity ligation assay (PLA), and quantitative bioluminescence resonance energy transfer (BRET) assay were employed to detect CXCR4-S1P<sub>1</sub> heteromerization. Functional properties of the heteromers were assessed using cAMP assay, G protein activation, &#x003b2;-arrestin recruitment, ligand binding, calcium mobilization, and transwell migration assays. S1P<sub>1</sub>-overexpressing Jurkat T cells were generated via lentiviral transduction, while S1P<sub>1</sub>-deficient KARPAS299 cells and &#x003b2;-arrestin1/2-deficient HEK293A cells were constructed using the CRISPR/Cas9 system.</p></sec><sec><title>Results</title><p id="Par3">CXCR4-S1P<sub>1</sub> heteromerization was observed in HEK293A cells overexpressing both receptors. The S1P/S1P<sub>1</sub> axis interfered with CXCR4-mediated signaling, while CXCR4 did not affect S1P<sub>1</sub>-mediated signaling, indicating a unidirectional modulation of CXCR4 by S1P<sub>1</sub>. CXCL12 binding to CXCR4 remained unchanged in the presence of S1P<sub>1</sub>, and interference of CXCL12-induced G&#x003b1;<sub>i</sub> activation by S1P<sub>1</sub> was observed in &#x003b2;-arrestin1/2-deficient cells. BRET analysis revealed that S1P<sub>1</sub> interfered with CXCR4-G&#x003b1;<sub>i</sub> pre-association and CXCR4 oligomerization, both of which are critical for CXCR4 function. Domain-swapping experiments identified transmembrane domain 3 of S1P<sub>1</sub> as essential for this modulation. In Jurkat T cells overexpressing S1P<sub>1</sub>, CXCR4-mediated signaling and cell migration were diminished, whereas these functions were enhanced in S1P<sub>1</sub>-deficient KARPAS299 cells. Co-activation of S1P<sub>1</sub> attenuated CXCL12-induced migration, while pretreatment with S1P or FTY720-phosphate increased CXCR4-mediated migration by downregulating surface S1P<sub>1</sub> in KARPAS299 cells. In primary T cells, PLA confirmed CXCR4-S1P<sub>1</sub> heteromerization, and S1P interfered with CXCL12-induced migration.</p></sec><sec><title>Conclusions</title><p id="Par4">This study identifies CXCR4-S1P<sub>1</sub> heteromers and demonstrates a unidirectional modulation of CXCR4 by S1P<sub>1</sub>. S1P<sub>1</sub> affects CXCR4 function by disrupting its G protein pre-association and oligomerization. These findings underscore the regulatory role of the S1P/S1P<sub>1</sub> axis in CXCR4 signaling within the heteromeric context and provide novel insights into the intricate mechanisms governing immune cell trafficking.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12964-025-02099-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>CXCR4</kwd><kwd>G protein-coupled receptor</kwd><kwd>Heteromer</kwd><kwd>S1P<sub>1</sub></kwd></kwd-group><funding-group><award-group><funding-source><institution>GPCR Therapeutics Inc.</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>2020R1A5A1018081</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">G protein-coupled receptors (GPCRs) are the largest family of plasma membrane proteins, characterized by seven transmembrane domains (TMs) that mediate intracellular signaling in response to diverse stimuli, such as light, neurotransmitters, lipid mediators, chemokines, and odorant molecules [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Ligand binding induces conformational changes in the GPCR, leading to the dissociation of the coupled G protein subunits [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. The human genome encodes sixteen G&#x003b1;, five G&#x003b2;, and twelve G&#x003b3; subunits, providing spatial and temporal regulation of GPCR signaling [<xref ref-type="bibr" rid="CR6">6</xref>]. Once dissociated, these G protein subunits propagate downstream signaling cascades, ultimately regulating a wide array of cellular and physiological responses [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. In addition to G protein-dependent signaling, GPCRs activate G protein-independent signaling through &#x003b2;-arrestins [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. These &#x003b2;-arrestins not only mediate receptor desensitization and internalization, but also facilitate sustained endosomal signaling in conjunction with G proteins following GPCR internalization [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par6">With approximately 800 GPCRs identified in humans, these receptors have gained significant attention due to their essential roles in numerous physiological processes. Over 30% of FDA-approved drugs target GPCRs, addressing a range of conditions such as hypertension, inflammatory disease, pain, and obesity [<xref ref-type="bibr" rid="CR14">14</xref>]. While GPCRs were traditionally considered to function as monomers, growing evidence has revealed the existence of GPCR heteromers [<xref ref-type="bibr" rid="CR15">15</xref>]. These heteromers exhibit distinct properties in ligand binding, downstream signaling, and cellular responses compared to their homomers. For instance, the &#x003b2;2-adrenergic receptor (&#x003b2;2AR) facilitates lymphocyte retention in lymph nodes (LNs) through physical interactions with chemokine receptors CXCR4 and CCR7 [<xref ref-type="bibr" rid="CR16">16</xref>]. Similarly, the lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) regulates lymphatic endothelial junctions by promoting sphingosine-1-phosphate receptor 1 (S1P<sub>1</sub>)/&#x003b2;-arrestin coupling [<xref ref-type="bibr" rid="CR17">17</xref>]. Using a high-throughput screening approach based on a bimolecular fluorescence complementation (BiFC) assay, we previously identified several GPCR heteromers, including CXCR4-&#x003b2;2AR [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], CXCR4-histamine receptor 1 [<xref ref-type="bibr" rid="CR20">20</xref>], and CXCR4-LPA<sub>1</sub> [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par7">CXCR4 is a widely expressed chemokine receptor critical for hematopoietic stem/progenitor cells (HSPCs) retention in the bone marrow (BM) and immune cell trafficking between secondary lymphoid organs and peripheral tissues [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. Clinically, CXCR4 inhibitors are used to mobilize HSPCs for transplantation and enhance the circulation of neutrophils and lymphocytes [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Similarly, lymphocyte retention in LNs is mediated by CXCR4 with their cognate ligands CXCL12 [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Furthermore, CXCR4 is overexpressed in various cancers, promoting tumor growth, invasion, metastasis, angiogenesis, and therapeutic resistance [<xref ref-type="bibr" rid="CR30">30</xref>]. Additionally, CXCR4 blockade has been shown to enhance the efficacy of immune checkpoint inhibitors in pancreatic and colorectal cancers by promoting T cell infiltration into tumors [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par8">CXCR4 exists in various structural states, including monomers, dimers, and oligomers, with oligomerization playing an essential role in its function [<xref ref-type="bibr" rid="CR23">23</xref>]. CXCL12 has been shown to induce CXCR4 oligomerization, and studies suggest that higher receptor expression levels correlate with enhanced oligomerization and increased basal activity [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Conversely, inverse agonists have been demonstrated to disrupt oligomers, thereby inhibiting CXCR4 activity [<xref ref-type="bibr" rid="CR35">35</xref>]. Beyond homomeric interactions, CXCR4 forms functional complexes with other surface molecules, such as CCR5, CXCR7, and CD4, further modulating its signaling and functional properties [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Interestingly, CD4 coexpression has been reported to impair CXCL12-induced CXCR4 nanoclustering, which results in diminished CXCR4-mediated signaling and migration in Jurkat cells [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par9">Sphingosine-1-phosphate (S1P) is a bioactive lipid that regulates cell migration, adhesion, survival, and proliferation through its five receptors S1P<sub>1</sub> to S1P<sub>5</sub> [<xref ref-type="bibr" rid="CR37">37</xref>]. S1P<sub>1</sub> is ubiquitously expressed, with the highest levels found in endothelial cells and lymphocytes [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. In endothelial cells, S1P<sub>1</sub> is essential for cardiovascular development and immune cell egress from lymphoid tissues [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Drugs targeting S1P<sub>1</sub>, such as those for multiple sclerosis, prevent lymphocyte egress from lymphoid tissues, thereby reducing autoreactive lymphocyte infiltration into the central nervous system [<xref ref-type="bibr" rid="CR42">42</xref>]. Additionally, S1P<sub>1</sub> contributes to cancer progression by promoting cancer cell migration and survival and enhancing regulatory T cell accumulation [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. While CXCR4 and S1P<sub>1</sub> are coexpressed in cancer and immune cells and participate in overlapping processes, their interaction remains complex. CXCR4 mediates HSPC retention in the BM, counteracted by the S1P gradient driving HSPC migration toward circulation [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Interestingly, S1P<sub>1</sub> expression is essential for CXCR4 antagonist-induced HSPC mobilization, further highlighting their interplay [<xref ref-type="bibr" rid="CR45">45</xref>], while the S1P<sub>1</sub> agonist FTY720 enhances CXCR4-mediated HSPC homing to the BM [<xref ref-type="bibr" rid="CR47">47</xref>]. Such opposing effects underscore the complexity of CXCR4-S1P<sub>1</sub> interactions, necessitating further study.</p><p id="Par10">In this study, we identified and validated the heteromerization between CXCR4 and S1P<sub>1</sub> and demonstrated how the S1P/S1P<sub>1</sub> axis modulates CXCR4 function by sequestering G proteins and disrupting oligomerization. Additionally, we observed that downregulation of S1P<sub>1</sub> by FTY720-phosphate (FTY720P) enhanced CXCL12-induced migration. Our findings provide novel insights into the molecular mechanisms governing CXCR4-S1P<sub>1</sub> interactions and their implications for immune cell trafficking.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Plasmids and cloning</title><p id="Par11">Human cDNAs for <italic>CXCR4</italic>, <italic>S1PR1</italic>, <italic>S1PR3</italic>, <italic>OPRM1</italic>, <italic>GNAI1</italic>, <italic>GNAI2</italic>, <italic>GNAI3</italic>, <italic>GNAOA</italic>, <italic>GNAOB</italic>, <italic>GNB1</italic>, and <italic>GNG2</italic> were obtained from the Missouri S&#x00026;T cDNA Resource Center. These cDNAs were cloned into pENTR201 or pENTR/D-TOPO vectors (Invitrogen) as described previously [<xref ref-type="bibr" rid="CR48">48</xref>]. If necessary, site-directed mutagenesis was employed to introduce a stop codon at the end of the gene of interest (GOI). The N-terminal fragment of Venus (VN) and the C-terminal fragment of Venus (VC) were derived from the AdBiFC vectors [<xref ref-type="bibr" rid="CR49">49</xref>]. Plasmids with Flag, HA, and MYC tags at the N-terminus of each GPCR were generated using one-step sequence- and ligation-independent cloning (SLIC) [<xref ref-type="bibr" rid="CR50">50</xref>]. pcDNA3.1-Rluc8 vectors were kindly provided by Hee-Jung Choi [<xref ref-type="bibr" rid="CR51">51</xref>], and pLenti6/V5-DEST Gateway vector was purchased from Invitrogen. pcDNA3.1 destination vectors with C-terminal VN, VC, Rluc8 and mCitrine (mCit) tags were constructed using SLIC. Subsequently, GOIs were cloned into pcDNA3.1 destination vectors using the Gateway cloning system according to the manufacturer&#x02019;s instructions (Invitrogen). For CRISPR/Cas9-mediated genome editing, a control guide RNA (sgControl, 5&#x02032;-ACGGAGGCTAAGCGTCGCAA-3&#x02032;), a guide RNA targeting human <italic>ARRB1</italic> (sg<italic>ARRB1</italic>, 5&#x02032;-TTCCCCGTGTCTTCGGGCCC-3&#x02032;; human <italic>ARRB2</italic> (sg<italic>ARRB2</italic>, 5&#x02032;-GCGGGACTTCGTAGATCACC-3&#x02032;), and human <italic>S1PR1</italic> (sg<italic>S1PR1</italic>, 5&#x02032;-CACCGGACGCTCAGGACGATAATTA-3&#x02032;) were cloned into lentiCRISPR-v2, a plasmid kindly provided by Feng Zhang (Addgene, #52961). Domain-swapped mutant forms of S1P<sub>1</sub>/S1P<sub>3</sub> were constructed using SLIC of each insert into the inverse PCR product of the backbone vectors. The sequences of TM3 of S1P<sub>1</sub> (KLTPAQWFLREGSMFVALSASVFSLLAIAIERYITMLKMKLHNG), TM4 of S1P<sub>1</sub> (SNNFRLFLLISACWVISLILGGLPIMGWNCISALSSCS), TM3 of S1P<sub>3</sub> (SLSPTVWFLREGSMFVALGASTCSLLAIAIERHLTMIKMRPYDA), and TM4 of S1P<sub>3</sub> (NKRHRVFLLIGMCWLIAFTLGALPILGWNCLHNLPDCS) were based on previous reports [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR52">52</xref>] and structural information (PDB: 3V2Y and 7C4S) [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p></sec><sec id="Sec4"><title>Cell culture</title><p id="Par12">HEK293A, Jurkat clone E6-1, and KARPAS299 cells were acquired from the Invitrogen, Korean Cell Line Bank, and the European Collection of Authenticated Cell Cultures, respectively. HEK293A cells were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) (HyClone, SH30243.01) supplemented with 10% fetal bovine serum (FBS) (HyClone, SH30084.03). Jurkat and KARPAS299 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (HyClone, SH30027.01) supplemented with 10% FBS. All cells were cultured at 37&#x000a0;&#x000b0;C in a 5% CO<sub>2</sub> humidified atmosphere. For transient transfection, HEK293A cells were seeded at a density of 4&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells per well in 6-well plates or 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells per well in 24-well plates. After 24&#x000a0;h, transient transfection was performed using PEI MAX (1&#x000a0;mg/ml) (Polysciences, #24765). Control Jurkat cells and Jurkat cells overexpressing MYC-tagged S1P<sub>1</sub> or S1P<sub>3</sub> were generated by transducing cells with lentivirus encoding empty vector and MYC-S1P<sub>1</sub> or -S1P<sub>3</sub>, followed by selection with 50&#x000a0;&#x000b5;g/ml blasticidin (InvivoGen). sg<italic>S1PR1</italic> and sgControl KARPAS299 cells were generated by transducing cells with lentivirus encoding CRISPR/Cas9-sg<italic>S1PR1</italic> or CRISPR/Cas9-sgControl, followed by selection with 0.5&#x02013;2.0&#x000a0;&#x000b5;g/ml puromycin (InvivoGen).</p></sec><sec id="Sec5"><title>Reagents and antibodies</title><p id="Par13">CXCL12 (#300&#x02013;28&#x000a0;A) was purchased from Peprotech. IT1t (#4596), S1P (#1370), and Ex26 (#5833) were purchased from Tocris Bioscience. Forskolin (#HY-15371) and FTY720P (#HY-15382) were purchased from MedChemExpress. Coelenterazine h (#301), coelenterazine 400a (#340), and coelenterazine native (#303) were purchased from Nanolight Technology. Normal rabbit IgG control antibody (#2729), anti-MYC-tag (9B11, #2276), and anti-HA-tag (C29F4, #3724) were purchased from Cell Signaling Technology. Anti-CXCR4 mouse monoclonal antibody (4G10, #sc-53534) was purchased from Santa Cruz Biotechnology. Mouse IgG control antibody (#I-2000) was purchased from Vector Laboratories. Anti-human S1P<sub>1</sub>/EDG-1 mouse monoclonal antibody (#MAB2016), anti-human S1P<sub>1</sub>/EDG-1 AF488-conjugated mouse monoclonal antibody (#FAB2016G), mouse F(ab)2 IgG (H&#x02009;+&#x02009;L) APC-conjugated antibody (#F0101B), and anti-human IgG APC-conjugated antibody (#0135) were purchased from R&#x00026;D Systems. Alexa Fluor 647 donkey anti-mouse IgG (H&#x02009;+&#x02009;L) (#31571), Goat anti-Rabbit IgG (H&#x02009;+&#x02009;L) secondary Alexa Fluor Plus 488 (#A32731) and Goat anti-Rabbit IgG (H&#x02009;+&#x02009;L) secondary Alexa Fluor Plus 568 (#A11011) were purchased from Invitrogen. PerCP/Cyanine5.5 anti-human CD3 (UCHT1, #300430) and PE anti-human CD4 (RPA-T4, #300508) were purchased from Biolegend. TZ14011-AF488 was synthesized by AnyGen (Korea). Anti-CXCR4 (Ulocuplumab) human monoclonal antibody was synthesized by Genscript [<xref ref-type="bibr" rid="CR55">55</xref>].</p></sec><sec id="Sec6"><title>Bimolecular fluorescence complementation (BiFC) assay and immunocytochemistry</title><p id="Par14">HEK293A cells were seeded in a 6-well plate and transfected with the indicated plasmids. One day after transfection, cells were detached using DPBS containing 2 mM EDTA and centrifuged at 500 <italic>g</italic> for 5&#x000a0;min. Cells were then resuspended in DMEM containing 10% FBS and transferred to a poly-D-lysine-coated 96-well clear bottom black plate (Greiner, #655090). The following day, cells were fixed with 4% paraformaldehyde for 30&#x000a0;min at room temperature, blocked with DPBS containing 0.5% BSA, and stained with anti-CXCR4 mouse monoclonal antibody (4G10, 1:200) and anti-HA-tag rabbit monoclonal antibody (C29F4, 1:2,000) overnight at 4&#x000a0;&#x000b0;C. After washing with DPBS, the samples were incubated with AF647-conjugated mouse secondary antibody (1:1,000) and AF568-conjugated rabbit secondary antibody (1:2,000). Following nuclear staining with Hoechst 33342, images were acquired using an LSM 700 laser scanning confocal microscope (Zeiss) with a 20&#x000d7; objective.</p></sec><sec id="Sec7"><title>Proximity ligation assay (PLA)</title><p id="Par15">PLA was performed using the NaveniFlex or NaveniFlex Cell MR Atto647N kits (Navinci) according to the manufacturer&#x02019;s instructions. In summary, HEK293A cells were seeded in a 6-well plate and transfected with plasmids encoding Flag-CXCR4, HA-S1P<sub>1</sub>, or HA-&#x000b5;OR1, either individually or in combination using PEI MAX (1&#x000a0;mg/ml) (Polysciences, #24765). 24&#x000a0;h post-transfection, cells were detached with DPBS containing 2 mM EDTA and centrifuged at 500 <italic>g</italic> for 5 min. The cell pellet was resuspended in DMEM containing 10% FBS and transferred to a poly-D-lysine-coated 96-well clear bottom black plate (Corning, #3340). The following day, cells were fixed with 4% paraformaldehyde for 30&#x000a0;min at room temperature and blocked with the kit&#x02019;s blocking solution. For single PLA, cells were stained with either an anti-CXCR4 mouse monoclonal antibody (Santa Cruz Biotechnology, #sc-53534, 4G10, 1:2,000) or an anti-HA-tag rabbit monoclonal antibody (Cell Signaling Technology, #3724, C29F4, 1:10,000) overnight at 4&#x000a0;&#x000b0;C. This was followed by incubation with anti-mouse probes or anti-rabbit probes, respectively, to detect GPCR homomers. For double PLA, cells were stained with both anti-CXCR4 and anti-HA-tag antibodies, followed by incubation with anti-mouse and anti-rabbit probes together to detect GPCR heteromers. The PLA signal was visualized using Atto647N red fluorescent dye. Following nuclear staining with Hoechst 33342, images were acquired using an LSM 700 laser scanning confocal microscope (Zeiss) with a 20&#x000d7; objective for quantification. For KARPAS299 cells and primary T cells, 2&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells were seeded onto slide glasses using a Cytospin at 500 <italic>g</italic> for 5 min. Cells were stained with probe-conjugated anti-CXCR4 human monoclonal antibody (Ulocuplumab, 10&#x000a0;&#x000b5;g/ml for KARPAS299 cells, 50&#x000a0;&#x000b5;g/ml for primary T cells) and an anti-S1P<sub>1</sub> mouse monoclonal antibody (R&#x00026;D systems, #MAB2016, clone 218713, 5 &#x000b5;g/ml) followed by anti-mouse probes. Ulocuplumab was synthesized by Genscript. Human IgG control antibody (#C0045-3) was purchased from Medical &#x00026; Biological Laboratories. Probe conjugation was performed by Navinci. Three images per sample were acquired, and the area of PLA signal and the numbers of nuclei were quantified using ImageJ software [<xref ref-type="bibr" rid="CR56">56</xref>].</p></sec><sec id="Sec8"><title>Quantitative BRET analysis</title><p id="Par16">To study the interaction between CXCR4 and S1P<sub>1</sub> or &#x000b5;OR1, fixed amounts of CXCR4-Rluc8, S1P<sub>1</sub>-Rluc8, or &#x000b5;OR1-Rluc8 and increasing amounts of CXCR4-mCit were used for transfection. For domain-swapped mutants, a fixed amount of CXCR4-Rluc8 and increasing amounts of mCit-tagged S1P<sub>1</sub>, S1P<sub>3</sub>, and their domain-swapped mutants were used for transfection. Two days after transfection, cells were detached using DPBS containing 2 mM EDTA, centrifuged at 500 <italic>g</italic> for 5&#x000a0;min, and resuspended in HBSS containing 20 mM HEPES and 0.1% BSA. Subsequently, cells were seeded into a 96-well white plate (Corning, #3917, or SPL, #34296) for measuring BRET signals and luminescence, and a 96-well clear bottom black plate (Corning, #3340) for measuring fluorescence. Coelenterazine h was added at a final concentration of 5 &#x000b5;M. For BRET signals and luminescence measurements, cells were read using a TriStar<sup>2</sup> LB 942 multimode microplate reader with a 480&#x000a0;nm filter for Rluc8 and a 540&#x000a0;nm filter for mCit, with a detection time of 0.1&#x000a0;s per well. For fluorescence measurements, cells were read using a TriStar<sup>2</sup> LB 942 multimode microplate reader with a 485&#x000a0;nm excitation filter and a 535&#x000a0;nm emission filter, with a detection time of 0.2&#x000a0;s per well. The Net BRET ratio was calculated by subtracting the BRET ratio of donor (Rluc8)-only-expressed sample from that of donor (Rluc8)-acceptor (mCit)-coexpressed sample. Saturation curves were analyzed through non-linear regression using GraphPad Prism 5 Software. BRET<sub>max</sub> and BRET<sub>50</sub> values were derived from the fitted saturation curves.</p></sec><sec id="Sec9"><title>Flow cytometry</title><p id="Par17">HEK293A cells were detached using Accutase (Sigma-Aldrich, #A6964). Cells were stained with indicated antibodies for 1&#x000a0;h on ice. Subsequently, cells were labeled with APC-conjugated anti-mouse, APC-conjugated anti-human, and AF488-conjugated anti-rabbit secondary antibodies. HEK293A, Jurkat, and KARPAS299 cells were analyzed using a LSRFortessa X-20 flow cytometer (BD Biosciences) and primary T cells were analyzed using a Canto II flow cytometer (BD biosciences). Flow cytometry data were processed with FlowJo software, and relative cell surface expression of GPCRs was expressed as mean fluorescence intensity (MFI).</p></sec><sec id="Sec10"><title>GloSensor cAMP assay</title><p id="Par18">Quantification of cAMP production was conducted using the GloSensor cAMP assay (Promega, #E1291). HEK293A cells were seeded in 6-well plates and transfected with plasmids encoding GloSensor-22&#x000a0;F, a biosensor variant with cAMP binding domain fused to a mutant form of luciferase [<xref ref-type="bibr" rid="CR57">57</xref>], and GPCRs. One day after transfection, cells were detached with DPBS containing 2 mM EDTA and centrifuged at 500 <italic>g</italic> for 5&#x000a0;min. Cells were then resuspended in DMEM without phenol red (Gibco, #21063-029) containing 5% FBS and seeded into a 96-well white plate (Corning, #3917, or SPL, #34296). The following day, cells were washed with assay buffer (CO<sub>2</sub>-independent medium (Gibco, #18045-088) with 0.1% BSA) and incubated in the dark at 37&#x000a0;&#x000b0;C for 2&#x000a0;h with 800&#x000a0;&#x000b5;g/ml D-luciferin. To measure ligand-induced inhibition of cAMP accumulation, cells were stimulated with 3 &#x000b5;M forskolin, followed by agonist treatment. Luminescence was measured using a TriStar<sup>2</sup> LB 942 multimode microplate reader (Berthold Technologies) with a 540&#x000a0;nm filter and a detection time of 1&#x000a0;s per well for a duration of 20&#x000a0;min.</p></sec><sec id="Sec11"><title>G protein activation assay</title><p id="Par19">Using TRUPATH system [<xref ref-type="bibr" rid="CR58">58</xref>], ligand-induced G protein activation was quantified by determining the dissociation between G&#x003b1; and G&#x003b2;&#x003b3; heterotrimers. Plasmids were kindly provided by Bryan Roth (Addgene, Kit #1000000163). GPCRs were cotransfected with the G&#x003b1;-Rluc8, G&#x003b2;, and GFP2-G&#x003b3;, each at 40 ng, in a 6-well plate as previously described [<xref ref-type="bibr" rid="CR58">58</xref>]. One day after transfection, cells were detached using DPBS containing 2 mM EDTA and centrifuged at 500 <italic>g</italic> for 5&#x000a0;min. Cells were then resuspended in DMEM without phenol-red containing 5% FBS and seeded into a 96-well white plate (Corning, #3917, or SPL, #34296). The following day, cells were washed with the assay buffer (HBSS containing 20 mM HEPES and 0.1% BSA) and treated with Coelenterazine 400a (5 &#x000b5;M) and CXCL12 or S1P. Antagonists were pretreated 30&#x000a0;min before agonist treatment. BRET2 signal was measured using a TriStar<sup>2</sup> LB 942 multimode microplate reader with a 410&#x000a0;nm filter for Rluc8 and a 515&#x000a0;nm filter for GFP2, with a detection time of 0.1&#x000a0;s per well. For ligand-induced G protein recruitment assay and detection of pre-association between GPCRs and G protein, CXCR4-mCit or S1P<sub>1</sub>-mCit, were cotransfected with G&#x003b1;<sub>i2</sub>-Rluc8, G&#x003b2;1, and G&#x003b3;2 in a 6-well plate in the presence or absence of MYC-S1P<sub>1</sub> or Flag-CXCR4. Each G&#x003b1; protein containing Rluc8 in the middle of the structure was cloned using SLIC as reported previously [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>]. Two days after transfection, cells were detached using DPBS containing 2 mM EDTA and centrifuged at 500 <italic>g</italic> for 5&#x000a0;min. Cells were resuspended in the assay buffer and treated with Coelenterazine h (5 &#x000b5;M). BRET1 signal was measured using a TriStar<sup>2</sup> LB 942 multimode microplate reader with a 480&#x000a0;nm filter for Rluc8 and a 540&#x000a0;nm filter for mCit, with a detection time of 0.1&#x000a0;s per well. The BRET ratio was calculated by dividing the long-wavelength emission (GFP2 or mCit signal) by the short-wavelength emission (Rluc8 signal). The Net BRET ratio was calculated by subtracting the BRET ratio of donor (Rluc8)-only-expressed sample from that of donor (Rluc8)-acceptor (mCit)-coexpressed sample. The &#x00394;BRET ratio was calculated by subtracting the BRET ratio of vehicle-treated sample from that of ligand-treated sample.</p></sec><sec id="Sec12"><title>&#x003b2;-arrestin recruitment assay</title><p id="Par21">Ligand-induced &#x003b2;-arrestin recruitment was quantified by measuring the recruitment of &#x003b2;-arrestin to GPCRs using BRET. HEK293A cells were transfected with mCit-&#x003b2;-arrestin2 and CXCR4-Rluc8 or S1P<sub>1</sub>-Rluc8 in the absence or presence of MYC-S1P<sub>1</sub> or Flag-CXCR4, respectively. One day after transfection, cells were detached using DPBS containing 2 mM EDTA and centrifuged at 500 <italic>g</italic> for 5&#x000a0;min. Cells were then resuspended in DMEM without phenol red containing 5% FBS and seeded into a 96-well white plate. The following day, cells were washed with the assay buffer and treated with the assay buffer containing the appropriate ligand and Coelenterazine h at a final concentration of 5 &#x000b5;M. BRET1 signals were read using a TriStar<sup>2</sup> LB 942 multimode microplate reader with a 480&#x000a0;nm filter for Rluc8 and a 540&#x000a0;nm filter for mCit, with a detection time of 0.1&#x000a0;s per well.</p></sec><sec id="Sec13"><title>CXCR4 ligand binding assay</title><p id="Par22">CXCL12 binding to CXCR4 was analyzed as previously reported [<xref ref-type="bibr" rid="CR21">21</xref>]. Cells were transfected with Gluc-CXCR4 alone or in combination with MYC-S1P<sub>1</sub>. One day after transfection, cells were detached using DPBS containing 2 mM EDTA and centrifuged at 500 <italic>g</italic> for 5&#x000a0;min. Cells were then resuspended in DMEM without phenol red containing 5% FBS and seeded into a 96-well white plate (Corning, #3917, or SPL, #34296). The following day, cells were washed with the assay buffer (HBSS containing 20 mM HEPES and 0.1% BSA). For the saturation binding assay, either vehicle or IT1t (10 &#x000b5;M) was treated for 30&#x000a0;min for total binding and non-specific binding, respectively. Subsequently, the indicated concentration of TZ14011-AF488 was treated with the assay buffer containing coelenterazine native at a final concentration of 5 &#x000b5;M. For competition binding assay, TZ14011-AF488 (10 nM) was treated for 30&#x000a0;min before the indicated concentration of unlabeled CXCL12. BRET1 signals were measured using a TriStar<sup>2</sup> LB 942 multimode microplate reader with a 480&#x000a0;nm filter for Gluc and a 540&#x000a0;nm filter for AF488, with a detection time of 0.1&#x000a0;s per well. The BRET ratio was calculated as described above. Saturation and competition curves were analyzed through non-linear regression with GraphPad Prism 5 Software. BRET<sub>max</sub> and BRET<sub>50</sub> values were derived from the fitted saturation curves.</p></sec><sec id="Sec14"><title>Calcium flux assay</title><p id="Par23">Jurkat cells were seeded in PDL (Sigma, #P1024)-coated 96-well black clear-bottom plates (Corning, #3340) at a density of 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells per well. After 24&#x000a0;h, cells were washed with assay buffer (HBSS without phenol red and with 20 mM HEPES and 0.1% bovine serum albumin) and stained with Cal-520AM (4.44&#x000a0;&#x000b5;g/ml; AAT Bioquest) for 2&#x000a0;h at 37&#x02103;. Cells were then washed three times with the assay buffer and incubated for an additional 30&#x000a0;min at 37&#x02103;. Plates were loaded into a FlexStation 3 multi-mode microplate reader (Molecular Devices), and ligands were injected. Intracellular calcium mobilization was detected for 130&#x000a0;s with an excitation of 485&#x000a0;nm and an emission of 525&#x000a0;nm. The area under the curve was calculated by GraphPad Prism 5 software.</p></sec><sec id="Sec15"><title>Transwell migration assay</title><p id="Par24">Jurkat, KARPAS299, and primary T cells were serum-starved overnight in RPMI 1640 containing 0.1% BSA. Cells were loaded into the upper chambers with 5&#x000a0;&#x003bc;m pore size membrane inserts (Corning, #3421) and allowed to migrate into the lower chambers containing CXCL12 or S1P. After incubation at 37&#x000a0;&#x000b0;C for 6&#x000a0;h, migrated cells were collected from the lower chamber and analyzed using a LSRFortessa X-20 flow cytometer with a flow rate of 2&#x000a0;&#x000b5;l/s for 40&#x000a0;s for Jurkat and KARPAS299 cells, and a Canto II flow cytometer with a flow rate of 1&#x000a0;&#x000b5;l/s for 30&#x000a0;s for primary T cells.</p></sec><sec id="Sec16"><title>Primary T cell isolation</title><p id="Par25">Human peripheral blood samples were obtained as leukocyte reduction system chambers from the Korean Redcross Blood Services with approval from the Institutional Review Board of Seoul National University (IRB No. E2212/003&#x02013;003). Peripheral blood mononuclear cells (PBMCs) were isolated through a density gradient centrifugation procedure using Histopaque (Sigma-Aldrich, #10771) and SepMate PBMC isolation tubes (STEMCELL Technologies, #86450). Primary CD3&#x02009;+&#x02009;CD4&#x02009;+&#x02009;T cells were isolated using EasySep Human CD4&#x02009;+&#x02009;T cell negative selection kit (STEMCELL Technologies, #17952), according to the manufacturer&#x02019;s instructions. The population and expression characteristics of PBMCs and CD4&#x02009;+&#x02009;T cells were analyzed using anti-CD3 (UCHT1) and anti-CD4 (RPA-T4) antibodies. Cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 50 IU of interleukin-2 (Biolegend, #589104).</p></sec><sec id="Sec17"><title>Statistical analysis</title><p id="Par26">Data are expressed as the mean &#x000b1; SEM or mean &#x000b1; SD from <italic>n</italic> independent experiments that were performed in duplicate or triplicate for each experiment on different days. Data were analyzed using GraphPad Prism 5 software. Statistical analysis was performed as described in the figure legends.</p></sec></sec><sec id="Sec18"><title>Results</title><sec id="Sec19"><title>Identification and validation of CXCR4-S1P<sub>1</sub> heteromerization</title><p id="Par27">Using a high-throughput screen based on a BiFC assay [<xref ref-type="bibr" rid="CR48">48</xref>], we identified several GPCR heteromers, including CXCR4-&#x003b2;2AR [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], CXCR4-histamine receptor 1 [<xref ref-type="bibr" rid="CR20">20</xref>], CXCR4-LPA<sub>1</sub> [<xref ref-type="bibr" rid="CR21">21</xref>], CXCR4-S1P<sub>1</sub>, and CXCR4-S1P<sub>3</sub>. While S1P<sub>1</sub> is known to interact with LPA<sub>1</sub> [<xref ref-type="bibr" rid="CR17">17</xref>] and CCR5 [<xref ref-type="bibr" rid="CR62">62</xref>], heteromerization between CXCR4 and S1P<sub>1</sub> has not, to our knowledge, been previously reported.</p><p id="Par28">In HEK293A cells overexpressing CXCR4-VN and CXCR4-VC, a BiFC signal was observed at the plasma membrane, indicating CXCR4 homomerization (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). Similarly, BiFC signals were detected in cells coexpressing CXCR4-VC and S1P<sub>1</sub>-VN (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B) as well as CXCR4-VC and S1P<sub>3</sub>-VN (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C). In contrast, no BiFC signal was observed in cells coexpressing CXCR4-VC and &#x000b5;OR1-VN, despite &#x000b5;OR1-VN being robustly expressed on the surface (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D), comparable to CXCR4, S1P<sub>1</sub>, and S1P<sub>3</sub> in non-permeabilized cells. These findings suggest the specific formation of CXCR4-S1P<sub>1</sub> and CXCR4-S1P<sub>3</sub> heteromers in cells overexpressing these GPCRs, while confirming the absence of interaction between CXCR4 and &#x000b5;OR1, consistent with previous reports [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par20">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Detection of heteromerization between CXCR4 and S1P1 in HEK293A cells. (A-D) BiFC assay was conducted to detect GPCR interactions in HEK293A cells. Cells were transfected with Flag-CXCR4-VC in combination with VN-tagged Flag-CXCR4 (A), HA-S1P1 (B), HA-S1P3 (C), and HA-&#x000b5;OR1 (D). Surface expression of GPCRs was visualized by staining cells with anti-CXCR4 (4G10) and anti-HA-tag (C29F4) antibodies. Cells were visualized using Hoechst 33342 (blue) for nuclei, AF647 (gray) for CXCR4, AF568 (red) for HA-tagged GPCRs (S1P1, S1P3, and &#x000b5;OR1), and BiFC signals (green). Scale bars: 10&#x000a0;&#x003bc;m. (E) PLA was performed to visualize the proximity between GPCRs in HEK293A cells expressing Flag-CXCR4 and HA-S1P1, Flag-CXCR4 and HA-&#x000b5;OR1, or either receptor alone using anti-CXCR4 (4G10) and anti-HA-tag (C29F4) antibodies. PLA signals were shown in red and cells were visualized using Hoechst 33342 (blue) for nuclei. Images are representative of three independent experiments. Data represent the mean&#x02009;&#x000b1;&#x02009;SEM of <italic>n</italic>&#x02009;=&#x02009;3 independent experiments. Statistical significance was tested using one-way ANOVA followed by Tukey&#x02019;s post-hoc test. ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. Scale bars: 10&#x000a0;&#x003bc;m. (F) Quantitative BRET assay was performed in HEK293A cells between CXCR4-mCit and Rluc8-tagged CXCR4, S1P1, or &#x000b5;OR1. The curves were fitted using a non-linear regression equation and represent three independent experiments</p></caption><graphic xlink:href="12964_2025_2099_Fig1_HTML" id="d33e858"/></fig>
</p><p id="Par30">To verify the interaction between CXCR4 and S1P<sub>1</sub>, we performed PLA, a highly sensitive and specific method for detecting protein interactions [<xref ref-type="bibr" rid="CR64">64</xref>]. First, we confirmed the expression of Flag-CXCR4, HA-S1P<sub>1</sub>, and HA-&#x000b5;OR1 by staining cells with anti-CXCR4 and anti-HA-tag antibodies under permeabilizing conditions. Immunocytochemistry revealed comparable levels and homogeneous surface expression of CXCR4, S1P<sub>1</sub>, and &#x000b5;OR1 in HEK293A cells (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S1</xref>A). However, single PLA for CXCR4 showed aggregated puncta (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S1</xref>B), likely reflecting its reported tendency to oligomerize [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], whereas discrete dot-like signals were observed for S1P<sub>1</sub> and &#x000b5;OR1 (Additional file 1: Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>C). This discrepancy arises because single PLA detects only GPCR homodimers and oligomers, not monomers. Moreover, the PLA signal area per cell for CXCR4 was larger than for S1P<sub>1</sub> and &#x000b5;OR1, supporting the presence of CXCR4 oligomers. Double PLA signals were detected exclusively in cells expressing both Flag-CXCR4 and HA-S1P<sub>1</sub>, confirming their specific interaction (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E). No signals were detected in cells expressing Flag-CXCR4 and HA-&#x000b5;OR1 or in cells expressing either Flag-CXCR4 or HA-S1P<sub>1</sub> alone. These observations suggest the specific interaction between CXCR4 and S1P<sub>1</sub>, ruling out non-selective aggregation due to receptor overexpression. Importantly, the presence of single PLA signals for GPCRs, but the absence of double PLA signals in CXCR4-&#x000b5;OR1 coexpression, indicates that CXCR4-S1P<sub>1</sub> heteromers form in a highly selective manner.</p><p id="Par31">To further validate heteromerization between CXCR4 and S1P<sub>1</sub>, we conducted a quantitative BRET assay using GPCRs tagged with either the BRET donor Rluc8 or the BRET acceptor mCit in HEK293A cells [<xref ref-type="bibr" rid="CR65">65</xref>]. Increasing the amounts of CXCR4-mCit with a fixed amount of CXCR4-Rluc8 or S1P<sub>1</sub>-Rluc8 resulted in hyperbolic increases in the BRET ratio (BRET<sub>max</sub> = 2.917<inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq1.gif"/></alternatives></inline-formula>0.0277, BRET<sub>50</sub>&#x02009;=&#x02009;2.739<inline-formula id="IEq2"><alternatives><tex-math id="M2">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq2.gif"/></alternatives></inline-formula>0.1077 for CXCR4-CXCR4; BRET<sub>max</sub> = 1.431<inline-formula id="IEq3"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq3.gif"/></alternatives></inline-formula>0.0247, BRET<sub>50</sub>&#x02009;=&#x02009;3.611<inline-formula id="IEq4"><alternatives><tex-math id="M4">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq4.gif"/></alternatives></inline-formula>0.2509 for CXCR4-S1P<sub>1</sub>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>F), suggesting the formation of both CXCR4 homomers and CXCR4-S1P<sub>1</sub> heteromers. In contrast, increasing the amounts of CXCR4-mCit with a fixed amount of &#x000b5;OR1-Rluc8 resulted in an almost linear increase in the BRET ratio, characterized by a low BRET<sub>max</sub> and high BRET<sub>50</sub> (BRET<sub>max</sub> = 0.9753<inline-formula id="IEq5"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq5.gif"/></alternatives></inline-formula>0.0524, BRET<sub>50</sub>&#x02009;=&#x02009;33.820<inline-formula id="IEq6"><alternatives><tex-math id="M6">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq6.gif"/></alternatives></inline-formula>3.6320), indicating non-specific random interactions between these two GPCRs. Together, these results confirm the specific heteromerization of CXCR4 with S1P<sub>1</sub>.</p></sec><sec id="Sec20"><title>S1P<sub>1</sub> modulates CXCR4 activation at the level of G protein activation</title><p id="Par32">To assess potential influence between GPCR expressions in HEK293A cells, flow cytometry analysis was performed. The coexpression of S1P<sub>1</sub> or &#x000b5;OR1 did not affect CXCR4 levels (Additional file 1: Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>A). Similarly, the presence of CXCR4 did not alter the surface expression of S1P<sub>1</sub> and &#x000b5;OR1 (Additional file 1: Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>B). To investigate the effect of S1P<sub>1</sub> on CXCR4, we monitored CXCR4-mediated cAMP response in HEK293A cells expressing CXCR4 alone or together with S1P<sub>1</sub> or &#x000b5;OR1. CXCL12 treatment reduced forskolin-induced cAMP accumulation in cells expressing CXCR4 alone (E<sub>max</sub> = 62.45<inline-formula id="IEq7"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq7.gif"/></alternatives></inline-formula>2.387, LogEC<sub>50</sub> = -11.17<inline-formula id="IEq8"><alternatives><tex-math id="M8">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq8.gif"/></alternatives></inline-formula>0.1066) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). Notably, this CXCL12-induced cAMP signaling was significantly counteracted in cells expressing both CXCR4 and S1P<sub>1</sub> (E<sub>max</sub> = 23.53<inline-formula id="IEq9"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq9.gif"/></alternatives></inline-formula>6.363, LogEC<sub>50</sub> = -9.986<inline-formula id="IEq10"><alternatives><tex-math id="M10">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq10.gif"/></alternatives></inline-formula>0.4188). The coexpression of &#x000b5;OR1, a receptor known not to interact with CXCR4, did not alter the CXCL12-induced cAMP signaling (E<sub>max</sub> = 57.65<inline-formula id="IEq11"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq11.gif"/></alternatives></inline-formula>4.569, LogEC<sub>50</sub> = -11.02<inline-formula id="IEq12"><alternatives><tex-math id="M12">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq12.gif"/></alternatives></inline-formula>0.1995). Although S1P<sub>1</sub> is also known as a G&#x003b1;<sub>i/o</sub>-coupled receptor [<xref ref-type="bibr" rid="CR66">66</xref>], the coexpression of CXCR4 did not affect the S1P-induced cAMP signaling (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). These findings suggest that S1P<sub>1</sub> interferes with CXCL12-induced cAMP signaling but not vice versa.</p><p id="Par33">To assess the effect of S1P<sub>1</sub> on CXCR4-mediated G protein activation, we utilized a BRET-based biosensor, measuring the decrease in the BRET ratio between G&#x003b1;-Rluc8 and G&#x003b3;-GFP2 [<xref ref-type="bibr" rid="CR58">58</xref>]. Given that G&#x003b1;<sub>i2</sub> is prevalent within the G&#x003b1;<sub>i/o</sub> subfamily [<xref ref-type="bibr" rid="CR67">67</xref>], we transfected HEK293A cells with G&#x003b1;<sub>i2</sub>-Rluc8, G&#x003b2;<sub>3</sub>, and G&#x003b3;<sub>9</sub>-GFP2. When cells expressing CXCR4 alone were treated with CXCL12, we observed a dose-dependent activation of G&#x003b1;<sub>i2</sub> (&#x00394;BRET<sub>max</sub> = -0.2914<inline-formula id="IEq13"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq13.gif"/></alternatives></inline-formula>0.0071, Log&#x00394;BRET<sub>50</sub> = -10.22<inline-formula id="IEq14"><alternatives><tex-math id="M14">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq14.gif"/></alternatives></inline-formula>0.0673) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). However, CXCL12-induced G&#x003b1;<sub>i2</sub> activation was significantly reduced when S1P<sub>1</sub> was coexpressed (&#x00394;BRET<sub>max</sub> = -0.1066<inline-formula id="IEq15"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq15.gif"/></alternatives></inline-formula>0.0084, Log&#x00394;BRET<sub>50</sub> = -9.968<inline-formula id="IEq16"><alternatives><tex-math id="M16">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq16.gif"/></alternatives></inline-formula>0.2081), with no comparable effect when &#x000b5;OR1 was coexpressed (&#x00394;BRET<sub>max</sub> = -0.2712<inline-formula id="IEq17"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq17.gif"/></alternatives></inline-formula>0.0059, Log&#x00394;BRET<sub>50</sub> = -10.35<inline-formula id="IEq18"><alternatives><tex-math id="M18">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq18.gif"/></alternatives></inline-formula>0.0636). However, the coexpression of CXCR4 did not influence S1P-induced G&#x003b1;<sub>i2</sub> activation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D). The inhibitory effect of S1P<sub>1</sub> on CXCL12-induced G&#x003b1;<sub>i2</sub> activation extended to other G&#x003b1;<sub>i/</sub>o subfamily members, including G&#x003b1;<sub>i1</sub>, G&#x003b1;<sub>i3</sub>, G&#x003b1;<sub>oA</sub>, and G&#x003b1;<sub>oB</sub> (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S3</xref>). These findings demonstrate that S1P<sub>1</sub> specifically interferes with CXCR4 activation without reciprocally affecting S1P<sub>1</sub> activation. Furthermore, given that S1P<sub>1</sub> coexpression did not alter CXCR4 surface expression, this modulation occurs through a functional mechanism rather than changes in receptor expression levels.</p><p id="Par29">
<fig id="Fig2"><label>Fig. 2</label><caption><p>S1P/S1P1 axis interferes with CXCR4-mediated cAMP signaling and G&#x003b1; activation. (<bold>A</bold>, <bold>B</bold>) CXCL12 (10 nM)- and S1P (10 nM)-induced inhibition of cAMP accumulation was measured using the 22 F cAMP sensor in HEK293A cells expressing CXCR4 alone or together with S1P1 or &#x000b5;OR1 (<bold>A</bold>), and in cells expressing S1P1 alone or together with CXCR4 (<bold>B</bold>). (<bold>C</bold>, <bold>D</bold>) CXCL12 (10 nM)- and S1P (10 nM)-induced G&#x003b1;i2 activation using G&#x003b1;-Rluc8, G&#x003b2;, and G&#x003b3;-GFP2 was measured in HEK293A cells expressing CXCR4 alone or together with S1P1 or &#x000b5;OR1 (<bold>C</bold>), and in cells expressing S1P1 alone or together with CXCR4 (<bold>D</bold>). (<bold>E</bold>,<bold> F</bold>) CXCL12 (10 nM)- and S1P (10 nM)-induced G&#x003b1;i2 recruitment to CXCR4 and S1P1 using G&#x003b1;-Rluc8, G&#x003b2;, and G&#x003b3; was assessed in HEK293A cells expressing CXCR4-mCit alone or together with S1P1 (<bold>E</bold>), and in cells expressing S1P1-mCit alone or together with CXCR4 (<bold>F</bold>). (<bold>G</bold>, <bold>H</bold>) Basal pre-association between GPCR (CXCR4 or S1P1) and G&#x003b1;i2 was assessed by BRET in HEK293A cells expressing CXCR4-mCit alone or together with S1P1 (<bold>G</bold>) and S1P1-mCit alone or together with CXCR4 (<bold>H</bold>) in the absence of ligand stimulation. (<bold>I</bold>) The effect of S1P1-selective antagonist Ex26 (10 &#x000b5;M) on CXCL12-induced G&#x003b1;i2 activation was determined in HEK293A cells expressing CXCR4 alone or together with S1P1. Data represent the mean&#x02009;&#x000b1;&#x02009;SEM of n&#x02009;=&#x02009;3 to 5 independent experiments. Statistical significance was tested using two-way ANOVA followed by Bonferroni&#x02019;s post-hoc test (<bold>A</bold>-<bold>D</bold>, <bold>I</bold>), one-way ANOVA followed by Tukey&#x02019;s post-hoc test (<bold>E</bold>, <bold>F</bold>), and two-tailed Student&#x02019;s t-test (<bold>G</bold>, <bold>H</bold>). *P&#x02009;&#x0003c;&#x02009;0.05; ***P&#x02009;&#x0003c;&#x02009;0.001; ns, not significant</p></caption><graphic xlink:href="12964_2025_2099_Fig2_HTML" id="d33e1262"/></fig>
</p></sec><sec id="Sec21"><title>S1P<sub>1</sub> interferes with CXCR4-mediated G&#x003b1;<sub>i</sub> activation by sequestering G&#x003b1;<sub>i</sub> proteins</title><p id="Par34">To investigate the effect of S1P<sub>1</sub> stimulation on CXCR4-mediated signaling, we examined CXCL12-induced G&#x003b1;<sub>i2</sub> recruitment to CXCR4 in the presence or absence of S1P in HEK293A cells by utilizing a BRET-based biosensor, which measures an increase in the BRET ratio between G&#x003b1;<sub>i2</sub>-Rluc8 and CXCR4-mCit [<xref ref-type="bibr" rid="CR68">68</xref>]. CXCL12 increased G&#x003b1;<sub>i2</sub> recruitment to CXCR4 in cells expressing CXCR4 alone, but consistent with the aforementioned findings about reduced CXCL12-induced G&#x003b1;<sub>i2</sub> activation, CXCL12-induced G&#x003b1;<sub>i2</sub> recruitment to CXCR4 was significantly reduced in cells coexpressing CXCR4 and S1P<sub>1</sub> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>E). When cells expressing CXCR4 alone were cotreated with CXCL12 and S1P, the recruitment of G&#x003b1;<sub>i2</sub> to CXCR4 remained unaffected. Interestingly, in cells expressing both receptors, cotreatment with CXCL12 and S1P further reduced CXCL12-induced G&#x003b1;<sub>i2</sub> recruitment to CXCR4. We next investigated whether CXCR4 stimulation affects G&#x003b1;<sub>i2</sub> recruitment to S1P<sub>1</sub> or not. S1P treatment induced G&#x003b1;<sub>i2</sub> recruitment to S1P<sub>1</sub> in cells expressing S1P<sub>1</sub> alone, and the coexpression of CXCR4 did not significantly influence S1P-induced G&#x003b1;<sub>i2</sub> recruitment to S1P<sub>1</sub> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F). In cells expressing S1P<sub>1</sub> alone, the addition of CXCL12 did not affect S1P-induced G&#x003b1;<sub>i2</sub> recruitment to S1P<sub>1</sub>. Even in cells expressing both CXCR4 and S1P<sub>1</sub>, G&#x003b1;<sub>i2</sub> recruitment to S1P<sub>1</sub> remained unaffected by CXCL12 treatment. These results suggest that S1P, through S1P<sub>1</sub>, further interferes with CXCL12-induced G&#x003b1;<sub>i2</sub> recruitment to CXCR4, but CXCR4 has no discernible impact on S1P<sub>1</sub> function under similar conditions.</p><p id="Par35">To investigate whether S1P<sub>1</sub> coexpression affects the basal association of G&#x003b1; with CXCR4, we measured BRET between CXCR4-mCit and G&#x003b1;<sub>i2</sub>-Rluc8 in the presence or absence of S1P<sub>1</sub>. Coexpression of S1P<sub>1</sub> significantly reduced the basal association of G&#x003b1;<sub>i2</sub> with CXCR4 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>G). In contrast, the expression of CXCR4 did not affect the basal association of G&#x003b1;<sub>i2</sub> with S1P<sub>1</sub> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>H). These results are consistent with prior observations, highlighting a unidirectional interference in which S1P<sub>1</sub> interferes with CXCR4 function without reciprocal regulation.</p><p id="Par36">Given that S1P<sub>1</sub> stimulation further interferes with CXCR4, we next examined whether endogenous S1P contributes to this interference. To address this, we monitored CXCL12-induced G&#x003b1;<sub>i2</sub> activation in the presence of 10 &#x000b5;M of Ex26, a potent and selective S1P<sub>1</sub> antagonist. In accordance with the results above, CXCL12-induced G&#x003b1;<sub>i2</sub> activation was significantly reduced in the presence of S1P<sub>1</sub> when cells were pretreated with vehicle (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>I). Pretreatment with Ex26 did not affect CXCR4 activation in cells expressing CXCR4 alone. However, in cells coexpressing CXCR4 and S1P<sub>1</sub>, Ex26 partially restored CXCL12-induced G&#x003b1;<sub>i2</sub> activation, suggesting that endogenous S1P contributes to the interference of CXCR4 signaling by S1P<sub>1</sub>. Intriguingly, despite the partial restoration, CXCL12-induced G&#x003b1;<sub>i2</sub> activation was not fully recovered by Ex26 treatment. These observations suggest that the interference of CXCR4 signaling by S1P<sub>1</sub> is not solely dependent on S1P<sub>1</sub> activation by endogenous S1P but also involves the apo form of S1P<sub>1</sub>.</p></sec><sec id="Sec22"><title>S1P<sub>1</sub> impairs CXCL12-induced CXCR4 oligomerization</title><p id="Par37">Since S1P<sub>1</sub> continued to interfere with CXCR4 activation even when S1P<sub>1</sub> stimulation was blocked, we further investigated the inhibitory mechanisms of S1P<sub>1</sub> toward CXCR4. It has been reported that heteromerization of GPCRs can affect the ligand binding affinity of their partner GPCRs through allosteric modulation [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. To investigate the impact of heteromerization on the ligand binding affinity of CXCR4, we performed a BRET-based ligand binding assay by measuring the BRET ratio between Gaussia luciferase (Gluc)-tagged CXCR4 and the Alexa Fluor 488-conjugated CXCR4 antagonist TZ14011 (TZ14011-AF488) [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. To exclude the non-specific signal caused by random collisions between donor and acceptor, we pretreated cells with the high-affinity CXCR4 antagonist IT1t for 30&#x000a0;min. As expected, increasing the concentration of TZ14011-AF488 led to a linear increase in the BRET ratio in the presence of IT1t, but a hyperbolic increase in the BRET ratio in the absence of IT1t (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). The specific BRET signal, which was defined as the difference between the total BRET signal obtained in the absence of IT1t and the non-specific BRET signal obtained in the presence of IT1t, was saturated at nanomolar concentrations, indicating that TZ14011-AF488 interacts with Gluc-CXCR4 with high affinity. The equilibrium dissociation constant (<italic>K</italic><sub>D</sub>) values between Gluc-CXCR4 and TZ14011-AF488 remained unaltered whether CXCR4 was expressed alone or coexpressed with S1P<sub>1</sub> (<italic>K</italic><sub>D</sub> = 4.607 <inline-formula id="IEq19"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq19.gif"/></alternatives></inline-formula> 0.8072 nM in cells expressing Gluc-CXCR4 alone; <italic>K</italic><sub>D</sub> = 4.507 <inline-formula id="IEq20"><alternatives><tex-math id="M20">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq20.gif"/></alternatives></inline-formula> 0.6392 nM in cells coexpressing Gluc-CXCR4 and S1P<sub>1</sub>). Subsequently, we performed a competitive ligand binding assay by treating cells with unlabeled CXCL12 to measure the dissociation of TZ14011-AF488 from Gluc-CXCR4. Similar concentrations of CXCL12 were required to dissociate TZ14011-AF488 from Gluc CXCR4, regardless of whether CXCR4 was expressed alone or coexpressed with S1P<sub>1</sub> (IC<sub>50</sub> = 38.30 <inline-formula id="IEq21"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq21.gif"/></alternatives></inline-formula> 10.08 nM in cells expressing Gluc-CXCR4 alone; IC<sub>50</sub> = 45.73 <inline-formula id="IEq22"><alternatives><tex-math id="M22">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\pm\:$$\end{document}</tex-math><inline-graphic xlink:href="12964_2025_2099_Article_IEq22.gif"/></alternatives></inline-formula> 13.19 nM in cells coexpressing Gluc-CXCR4 and S1P<sub>1</sub>) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). These results suggest that the ligand binding affinity of CXCR4 is not affected by heteromerization with S1P<sub>1</sub>.</p><p id="Par38">
<fig id="Fig3"><label>Fig. 3</label><caption><p>S1P<sub>1</sub> impairs CXCR4 oligomerization without affecting ligand binding or &#x003b2;-arrestin-mediated desensitization. (<bold>A</bold>) BRET-based ligand binding assay was performed in HEK293A cells expressing Gluc-CXCR4 alone (left) or together with S1P<sub>1</sub> (right). The selective CXCR4 antagonist TZ14011-AF488 was used as an acceptor to measure specific binding. IT1t (10 &#x000b5;M) was pretreated to account for non-specific BRET signal. Specific BRET signal was defined as the difference between the total BRET signal and the non-specific BRET signal. (<bold>B</bold>) Competitive binding was assessed using unlabeled CXCL12 (3 nM to 3 &#x000b5;M) in the presence of TZ14011-AF488 (10 nM) in cells expressing Gluc-CXCR4 alone or together with S1P<sub>1</sub>. (<bold>C</bold>,<bold> D</bold>) CXCL12 (10 nM)-induced G&#x003b1;<sub>i2</sub> activation (<bold>C</bold>) and G&#x003b1;<sub>i2</sub> recruitment to CXCR4 after cotreatment with S1P (10 nM) (<bold>D</bold>) were measured in control (sgControl) and &#x003b2;-arrestin1/2-deficient (sg<italic>ARRB1/2</italic>) HEK293A cells expressing CXCR4 alone or together with S1P<sub>1</sub>. (<bold>E</bold>) Quantitative BRET assay was performed in HEK293A cells between CXCR4-mCit and CXCR4-Rluc8 in the absence or presence of S1P<sub>1</sub> and/or CXCL12 (10 nM). The curves were fitted using a non-linear regression equation, as a bar graph summarizing BRET<sub>max</sub> and BRET<sub>50</sub> of each condition. Data represent the mean&#x02009;&#x000b1;&#x02009;SEM of <italic>n</italic>&#x02009;=&#x02009;3 independent experiments (<bold>A</bold>-<bold>D</bold>) and the mean&#x02009;&#x000b1;&#x02009;SD of <italic>n</italic>&#x02009;=&#x02009;5 independent experiments (<bold>E</bold>). Statistical significance was tested using two-tailed Student&#x02019;s <italic>t</italic>-test for <italic>K</italic><sub>D</sub> of specific binding (<bold>A</bold>) and for IC<sub>50</sub> of the curves (<bold>B</bold>), two-way ANOVA followed by Bonferroni&#x02019;s post-hoc test (<bold>C</bold>, <bold>D</bold>), and one-way ANOVA followed by Tukey&#x02019;s post-hoc test (<bold>E</bold>). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; ns, not significant</p></caption><graphic xlink:href="12964_2025_2099_Fig3_HTML" id="d33e1583"/></fig>
</p><p id="Par39">Traditionally, &#x003b2;-arrestins mediate GPCR desensitization by blocking G protein interactions and promoting receptor internalization [<xref ref-type="bibr" rid="CR72">72</xref>]. However, some GPCRs can form super-complexes consisting of the GPCR, &#x003b2;-arrestin, and G protein, enabling sustained signaling within intracellular compartments [<xref ref-type="bibr" rid="CR11">11</xref>]. Notably, heteromerization with other GPCRs has been shown to enhance &#x003b2;-arrestin recruitment, leading to the inhibition of the primary receptor&#x02019;s function [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. In light of these findings, we examined the effect of S1P<sub>1</sub> on &#x003b2;-arrestin recruitment to CXCR4. Increasing the amounts of mCit-&#x003b2;-arrestin2 with a fixed amount of CXCR4-Rluc8 resulted in hyperbolic increases in the BRET ratio (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S4</xref>A), indicating complex formation between CXCR4 and &#x003b2;-arrestin2. Coexpression of S1P<sub>1</sub> slightly but significantly increased BRET<sub>max</sub> values for the CXCR4-&#x003b2;-arrestin2 complex (BRET<sub>max</sub> = 0.2138&#x02009;&#x000b1;&#x02009;0.0128 in cells expressing CXCR4-Rluc8 alone; BRET<sub>max</sub> = 0.2771&#x02009;&#x000b1;&#x02009;0.0085 in cells coexpressing CXCR4-Rluc8 and Myc-S1P<sub>1</sub>), suggesting that the amount of the CXCR4-&#x003b2;-arrestin2 complex increases in the presence of S1P<sub>1</sub>. Furthermore, S1P treatment enhanced &#x003b2;-arrestin2 recruitment to CXCR4 in the presence of S1P<sub>1</sub> (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S4</xref>B), whereas CXCL12 treatment did not affect &#x003b2;-arrestin2 recruitment to S1P<sub>1</sub> in the presence of CXCR4 (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S4</xref>C). These results suggest that S1P-induced &#x003b2;-arrestin2 recruitment to CXCR4 may contribute to the interference of CXCR4 signaling by the S1P/S1P<sub>1</sub> axis. However, CXCR4-mediated G protein activation and G protein recruitment to CXCR4 were still inhibited by the S1P/S1P<sub>1</sub> axis in &#x003b2;-arrestin1/2-deficient HEK293A cells, similar to what was observed in control cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C, D, Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S4</xref>D). These observations suggest the possibility of an alternative inhibitory mechanism by S1P<sub>1</sub> toward CXCR4 that operates independently of &#x003b2;-arrestin involvement. Notably, CXCR4-mediated G protein activation and G protein recruitment to CXCR4 were not increased in &#x003b2;-arrestin1/2-deficient cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C, D), indicating that CXCR4 desensitization and internalization are largely independent of &#x003b2;-arrestins. This conclusion is supported by recent findings showing that CXCL12-induced CXCR4 internalization remains unaffected in &#x003b2;-arrestin1/2-deficient cells [<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par40">CXCR4 is known to form dimers and oligomers, and perturbations in CXCR4 oligomerization have been shown to disrupt its signaling and function [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Interestingly, coexpression with CD4 diminishes CXCL12-induced CXCR4 nanoclustering, leading to impaired CXCR4-mediated signaling and migration in Jurkat cells [<xref ref-type="bibr" rid="CR34">34</xref>]. To investigate the effect of S1P<sub>1</sub> on CXCR4 oligomerization, we conducted a quantitative BRET assay. The coexpression of S1P<sub>1</sub> increased the BRET<sub>50</sub> and decreased the BRET<sub>max</sub> values for CXCR4-Rluc8 and CXCR4-mCit (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>E; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), indicating reduced affinity between CXCR4 protomers and decreased oligomerization at steady state. Notably, CXCL12 treatment lowered the BRET<sub>50</sub> for CXCR4 homomers only in the absence of S1P<sub>1</sub>, suggesting that S1P<sub>1</sub> interferes with the CXCL12-induced increase in affinity between CXCR4 protomers. These findings suggest that S1P<sub>1</sub> affects CXCR4 function by disrupting its oligomerization.</p><p id="Par41">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>BRET<sub>max</sub> and BRET<sub>50</sub> values from the quantitative BRET assay between CXCR4-Rluc8 and CXCR4-mCit</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Without S1P<sub>1</sub></th><th align="left" colspan="2">With S1P<sub>1</sub></th></tr><tr><th align="left">Vehicle</th><th align="left">CXCL12</th><th align="left">Vehicle</th><th align="left">CXCL12</th></tr></thead><tbody><tr><td align="left">BRET<sub>max</sub></td><td align="left">2.998&#x02009;&#x000b1;&#x02009;0.1255</td><td align="left">3.083&#x02009;&#x000b1;&#x02009;0.1056</td><td align="left">2.546&#x02009;&#x000b1;&#x02009;0.1049</td><td align="left">2.670&#x02009;&#x000b1;&#x02009;0.1109</td></tr><tr><td align="left">BRET<sub>50</sub></td><td align="left">15.61&#x02009;&#x000b1;&#x02009;2.814</td><td align="left">9.534&#x02009;&#x000b1;&#x02009;1.716</td><td align="left">22.84&#x02009;&#x000b1;&#x02009;3.430</td><td align="left">20.07&#x02009;&#x000b1;&#x02009;3.315</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec23"><title>TM3 of S1P<sub>1</sub> is important for the modulation of CXCR4 within the heteromer complex</title><p id="Par42">Previous studies have demonstrated the significance of TM4 of S1P<sub>1</sub> in its interaction with CD69 and crosstalk with LPA<sub>1</sub> [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. For dopamine receptor D2 (D2R), TM4 and TM5 form the interaction interface of the D2R dimer [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>], and TM3 is also crucial for dimer formation [<xref ref-type="bibr" rid="CR78">78</xref>]. To investigate the interaction interface between CXCR4 and S1P<sub>1</sub>, we generated domain-swapped mutants of S1P<sub>1</sub>. Because S1P<sub>3</sub> showed BiFC signals with CXCR4 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C) and is reported to promote CXCR4 activation [<xref ref-type="bibr" rid="CR79">79</xref>], we constructed S1P<sub>1</sub>(TM3) and S1P<sub>1</sub>(TM4) mutants by replacing TM3 and TM4 of S1P<sub>1</sub> with the corresponding domains from S1P<sub>3</sub> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). We also generated S1P<sub>3</sub>(TM3) and S1P<sub>3</sub>(TM4) mutants by replacing TM3 and TM4 of S1P<sub>3</sub> with the corresponding domains from S1P<sub>1</sub>. Immunocytochemistry and flow cytometry analysis confirmed that MYC-tagged S1P<sub>1</sub>, S1P<sub>3</sub>, and their domain-swapped mutants were properly expressed on the surface of HEK293A cells (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S5</xref>A, B). Subsequently, we investigated whether CXCR4 forms heteromers with S1P<sub>1</sub>, S1P<sub>3</sub>, or the domain-swapped mutants through quantitative BRET analysis. Increasing the amounts of mCit-tagged S1P<sub>1</sub>, S1P<sub>3</sub>, or the mutants with a fixed amount of CXCR4-Rluc8 all led to hyperbolic increases in the BRET ratio (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B, C; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). These results suggest that CXCR4 indeed forms heteromers with S1P<sub>1</sub> and S1P<sub>3</sub>, regardless of whether TM3 or TM4 is replaced with the corresponding domain from S1P<sub>3</sub> and S1P<sub>1</sub>, respectively.</p><p id="Par43">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Identification of the S1P<sub>1</sub> domain responsible for CXCR4 inhibition by S1P<sub>1</sub>. (<bold>A</bold>) Schematic diagram of CXCL12-induced G protein activation in HEK293A cells coexpressing CXCR4 and wildtype or domain-swapped mutants of S1P<sub>1</sub> or S1P<sub>3</sub>. (<bold>B</bold>,<bold> C</bold>) Quantitative BRET assay was performed between CXCR4-Rluc8 and mCit-tagged S1P<sub>1</sub>, S1P<sub>1</sub>(TM3), or S1P<sub>1</sub>(TM4) (<bold>B</bold>) and mCit-tagged S1P<sub>3</sub>, S1P<sub>3</sub>(TM3), or S1P<sub>3</sub>(TM4) (<bold>C</bold>). The curves were fitted using a non-linear regression equation and represent three independent experiments. (<bold>D</bold>,<bold> E</bold>) CXCL12-induced cAMP signaling was measured in HEK293A cells expressing CXCR4 alone or together with S1P<sub>1</sub>, S1P<sub>1</sub>(TM3), or S1P<sub>1</sub>(TM4) (<bold>D</bold>) or together with S1P<sub>3</sub>, S1P<sub>3</sub>(TM3), or S1P<sub>3</sub>(TM4) (<bold>E</bold>). (<bold>F</bold>,<bold> G</bold>) CXCL12-induced G&#x003b1;<sub>i2</sub> activation was measured in HEK293A cells expressing CXCR4 alone or together with S1P<sub>1</sub>, S1P<sub>1</sub>(TM3), or S1P<sub>1</sub>(TM4) (<bold>F</bold>) or together with S1P<sub>3</sub>, S1P<sub>3</sub>(TM3), or S1P<sub>3</sub>(TM4) (<bold>G</bold>). Data represent the mean&#x02009;&#x000b1;&#x02009;SEM of <italic>n</italic>&#x02009;=&#x02009;4 independent experiments. Statistical significance was tested using two-way ANOVA followed by Bonferroni&#x02019;s post-hoc test (<bold>D</bold>-<bold>G</bold>). ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; ns, not significant</p></caption><graphic xlink:href="12964_2025_2099_Fig4_HTML" id="d33e1964"/></fig>
</p><p id="Par44">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>BRET<sub>max</sub> and BRET<sub>50</sub> values from the quantitative BRET assay between CXCR4-Rluc8 and mcit-tagged S1P<sub>1</sub>, S1P<sub>3</sub>, or the domain-swapped mutants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">-Rluc8</th><th align="left" colspan="6">CXCR4</th></tr></thead><tbody><tr><td align="left">-mCit</td><td align="left">S1P<sub>1</sub></td><td align="left">S1P<sub>1</sub>(TM3)</td><td align="left">S1P<sub>1</sub>(TM4)</td><td align="left">S1P<sub>3</sub></td><td align="left">S1P<sub>3</sub>(TM3)</td><td align="left">S1P<sub>3</sub>(TM4)</td></tr><tr><td align="left">BRET<sub>max</sub></td><td align="left">1.523&#x02009;&#x000b1;&#x02009;0.0284</td><td align="left">1.745&#x02009;&#x000b1;&#x02009;0.0379</td><td align="left">1.422&#x02009;&#x000b1;&#x02009;0.0314</td><td align="left">1.373&#x02009;&#x000b1;&#x02009;0.0253</td><td align="left">0.955&#x02009;&#x000b1;&#x02009;0.0175</td><td align="left">1.903&#x02009;&#x000b1;&#x02009;0.0327</td></tr><tr><td align="left">BRET<sub>50</sub></td><td align="left">5.169&#x02009;&#x000b1;&#x02009;0.3383</td><td align="left">7.237&#x02009;&#x000b1;&#x02009;0.5014</td><td align="left">7.191&#x02009;&#x000b1;&#x02009;0.5593</td><td align="left">6.471&#x02009;&#x000b1;&#x02009;0.3773</td><td align="left">6.968&#x02009;&#x000b1;&#x02009;0.4726</td><td align="left">12.69&#x02009;&#x000b1;&#x02009;0.6873</td></tr></tbody></table></table-wrap>
</p><p id="Par45">We next examined the influence of the domain-swapped mutants of S1P<sub>1</sub> and S1P<sub>3</sub> on CXCR4 activation by analyzing CXCL12-induced cAMP signaling and G&#x003b1;<sub>i2</sub> activation in HEK293A cells coexpressing CXCR4 with either S1P<sub>1</sub>, S1P<sub>3</sub>, or each of the mutants. As previously mentioned, CXCL12-induced cAMP signaling was notably reduced when S1P<sub>1</sub> was coexpressed (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D). Interestingly, the coexpression of S1P<sub>1</sub>(TM3) did not significantly affect CXCL12-induced cAMP signaling, while S1P<sub>1</sub>(TM4) coexpression had a similar effect on CXCL12-induced cAMP signaling as S1P<sub>1</sub> coexpression. These observations suggest that TM3 of S1P<sub>1</sub> is necessary for CXCR4 regulation by S1P<sub>1</sub>, while TM4 of S1P<sub>1</sub> is not. Although S1P<sub>3</sub> forms heteromers with CXCR4, this interaction did not significantly affect CXCL12-induced cAMP signaling (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>E). Additionally, we observed that CXCL12-induced cAMP signaling was significantly reduced when S1P<sub>3</sub>(TM3) was coexpressed, but not when S1P<sub>3</sub>(TM4) was coexpressed, highlighting the importance of TM3 of S1P<sub>1</sub> in CXCR4 inhibition by S1P<sub>1</sub>. Similarly, CXCL12-induced G&#x003b1;<sub>i2</sub> activation was significantly reduced when S1P<sub>1</sub>, S1P<sub>1</sub>(TM4), or S1P<sub>3</sub>(TM3) were coexpressed, but not when S1P<sub>1</sub>(TM3), S1P<sub>3</sub>, or S1P<sub>3</sub>(TM4) were coexpressed (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>F, G). The inhibition of CXCR4 by S1P<sub>1</sub> was not due to a decrease in CXCR4 expression, as flow cytometry analysis revealed no significant alteration in the surface expression of CXCR4 in HEK293A cells expressing CXCR4 alone or in combination with S1P<sub>1</sub>, S1P<sub>3</sub>, or any of the mutants (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S5</xref>C). Taken together, these findings suggest that TM3 of S1P<sub>1</sub> is the regulatory motif for CXCR4 within the heteromer complex.</p></sec><sec id="Sec24"><title>S1P<sub>1</sub> coexpression interferes with CXCR4-mediated intracellular signaling and cell migration in Jurkat cells</title><p id="Par46">To further investigate the influence of S1P<sub>1</sub> on CXCR4, we established an S1P<sub>1</sub>-overexpressing cell line using lentivirus encoding MYC-tagged S1P<sub>1</sub> in Jurkat T lymphoblast cells, which are widely studied in CXCR4-mediated cell migration and signaling [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. Flow cytometry analysis confirmed the increased surface expression of MYC-tagged S1P<sub>1</sub> in the S1P<sub>1</sub>-expressing (hereafter &#x0201c;S1P<sub>1</sub>&#x0201d;) Jurkat cells compared to the control cells, which were transduced with lentivirus encoding empty vector (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A). The surface expression of CXCR4 did not change significantly in cells overexpressing S1P<sub>1</sub> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B). Interestingly, intracellular calcium flux and cell migration toward CXCL12 were significantly impaired in the S1P<sub>1</sub> Jurkat cells compared to the control cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>C, D). To validate the role of S1P<sub>1</sub> in interfering with CXCR4-mediated cell migration, we stably overexpressed S1P<sub>3</sub> in Jurkat cells as a negative control. Flow cytometry analysis confirmed the proper surface expression of MYC-tagged S1P<sub>3</sub> in the S1P<sub>3</sub>-expressing (hereafter &#x0201c;S1P<sub>3</sub>&#x0201d;) Jurkat cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A). The surface expression of CXCR4 remained consistent between the control and S1P<sub>3</sub> Jurkat cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B). In contrast to the findings observed in the S1P<sub>1</sub> Jurkat cells, CXCL12-induced intracellular calcium flux and cell migration were not altered significantly in the S1P<sub>3</sub> Jurkat cells compared to the control cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>C, D). Consistent with the results in G protein activation in HEK293A cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D-F), these results indicate that S1P<sub>1</sub> specifically interferes with CXCR4 activity in Jurkat cells, while S1P<sub>3</sub> does not exhibit an inhibitory effect. <fig id="Fig5"><label>Fig. 5</label><caption><p>Inhibition of CXCR4-mediated signaling and migration by S1P<sub>1</sub> in Jurkat cells. (<bold>A</bold>,<bold> B</bold>) Surface expression of S1P<sub>1</sub>, S1P<sub>3</sub>, and CXCR4 in Jurkat cells overexpressing Myc-S1P<sub>1</sub> or Myc-S1P<sub>3</sub>. Anti-MYC-tag (9B11) antibody was used to detect S1P<sub>1</sub> and S1P<sub>3</sub> (<bold>A</bold>) and anti-CXCR4 (Ulocuplumab) antibody was used to detect CXCR4 (<bold>B</bold>) in the control (red), S1P<sub>1</sub> (blue), and S1P<sub>3</sub> (green) overexpressing cells. Gray histograms represent staining with IgG control antibody. Representative histograms of four independent experiments are shown. Data represent the mean&#x02009;&#x000b1;&#x02009;SD of <italic>n</italic>&#x02009;=&#x02009;4 independent experiments. (<bold>C</bold>,<bold> D</bold>) CXCL12-induced intracellular calcium flux (<bold>C</bold>) and cell migration (<bold>D</bold>) were detected in the control (red), S1P<sub>1</sub> (blue), and S1P<sub>3</sub> (green) overexpressing cells after treatment with CXCL12 in a dose-dependent manner. Data represent the mean&#x02009;&#x000b1;&#x02009;SEM of <italic>n</italic>&#x02009;=&#x02009;3 to 4 independent experiments. Statistical significance was tested using one-way ANOVA followed by Dunnett&#x02019;s post-hoc test (<bold>A</bold>, <bold>B</bold>) and two-way ANOVA followed by Bonferroni&#x02019;s post-hoc test (<bold>C</bold>, <bold>D</bold>). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; ns, not significant</p></caption><graphic xlink:href="12964_2025_2099_Fig5_HTML" id="d33e2293"/></fig></p></sec><sec id="Sec25"><title>S1P<sub>1</sub> forms heteromers with CXCR4 and interferes with cell migration toward CXCL12 in T cells endogenously expressing both receptors</title><p id="Par47">KARPAS299 is a human non-Hodgkin&#x02019;s lymphoma T cell line that inherently expresses both CXCR4 and S1P<sub>1</sub> [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Previous studies have proposed neutralizing CXCR4 as a therapeutic approach for non-Hodgkin&#x02019;s lymphoma [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>] and have elucidated CXCR4-mediated cell migration in KARPAS299 cells [<xref ref-type="bibr" rid="CR85">85</xref>]. Given the endogenous coexpression of CXCR4 and S1P<sub>1</sub> in these cells, we investigated the heteromerization of these GPCRs and the effect of S1P<sub>1</sub> on CXCR4-mediated functions. To examine whether S1P<sub>1</sub> directly interferes with CXCR4 activity, we deleted the <italic>S1PR1</italic> gene in KARPAS299 cells using the CRISPR/Cas9 system.</p><p id="Par48">Single PLA and flow cytometry revealed a significant reduction in S1P<sub>1</sub> expression in sg<italic>S1PR1</italic>-treated cells (referred to as &#x0201c;S1P<sub>1</sub>-deficient cells&#x0201d;) compared to sgControl-treated cells (referred to as &#x0201c;control cells&#x0201d;) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A, Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S6</xref>A), while CXCR4 expression remained unaffected (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>B, Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S6</xref>B). Additionally, S1P-induced migration was markedly diminished in S1P<sub>1</sub>-deficient cells, confirming the effective downregulation of S1P<sub>1</sub> (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S6</xref>C). CXCR4-S1P<sub>1</sub> double PLA signals were observed in control cells, but were absent in S1P<sub>1</sub>-deficient cells, supporting the presence of CXCR4-S1P<sub>1</sub> heteromers in KARPAS299 cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C, D).</p><p id="Par49">
<fig id="Fig6"><label>Fig. 6</label><caption><p>S1P/S1P<sub>1</sub> axis inhibits CXCR4-mediated migration of KARPAS299 cells endogenously expressing CXCR4 and S1P<sub>1</sub> through heteromer formation. (<bold>A-D</bold>) Detection of CXCR4-S1P<sub>1</sub> heteromers in control and S1P<sub>1</sub>-deficient KARPAS299 cells. KARPAS299 cells were transduced with lentivirus encoding CRISPR/Cas9 and sgControl or sg<italic>S1PR1</italic>, and cells were stained with anti-S1P<sub>1</sub> (#218713) antibody alone for both probes 1 and 2 (<bold>A</bold>), anti-CXCR4 (Ulocuplumab) antibody alone for both probes 1 and 2 (<bold>B</bold>), anti-CXCR4 for probe 1 and anti-S1P<sub>1</sub> for probe 2 (<bold>C</bold>), and anti-S1P<sub>1</sub> for probe 1 and anti-CXCR4 for probe 2 (<bold>D</bold>) to identify S1P<sub>1</sub> homomers, CXCR4 homomers, and S1P<sub>1</sub>-CXCR4 heteromers. Images are representative of three independent experiments. Scale bars: 10&#x000a0;&#x003bc;m. (<bold>E</bold>,<bold> F</bold>) Transwell migration assays were performed in control and S1P<sub>1</sub>-deficient KARPAS299 cells. The effect of S1P<sub>1</sub> on CXCL12-induced migration (<bold>E</bold>) and the effect of S1P (10 nM) on CXCL12 (30 nM)-induced migration (<bold>F</bold>). (<bold>G-I</bold>) The effect of S1P<sub>1</sub> agonist, S1P (10 nM) and FTY720P (100 nM), pretreatment (3&#x000a0;h) on CXCL12-induced migration and the surface expression of S1P<sub>1</sub> and CXCR4 were assessed in KARPAS299 cells. Transwell migration assays were performed in control and S1P<sub>1</sub>-deficient KARPAS299 cells (<bold>G</bold>) and flow cytometry analysis was conducted to analyze surface expression of S1P<sub>1</sub> (<bold>H</bold>) and CXCR4 (<bold>I</bold>) in KARPAS299 cells using anti-S1P<sub>1</sub> (#218713) and anti-CXCR4 (Ulocuplumab) antibodies. Data represent the mean&#x02009;&#x000b1;&#x02009;SEM of <italic>n</italic>&#x02009;=&#x02009;3 to 4 independent experiments (<bold>A</bold>-<bold>G</bold>) and the mean&#x02009;&#x000b1;&#x02009;SD of <italic>n</italic>&#x02009;=&#x02009;3 independent experiments (<bold>H</bold>, <bold>I</bold>). Statistical significance was tested using two-tailed Student&#x02019;s <italic>t</italic>-test (<bold>A</bold>-<bold>D</bold>), two-way ANOVA followed by Bonferroni&#x02019;s post-hoc test (<bold>E</bold>, <bold>F</bold>), and one-way ANOVA followed by Dunnett&#x02019;s post-hoc test with vehicle-treated condition (<bold>G</bold>-<bold>I</bold>). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; ns, not significant</p></caption><graphic xlink:href="12964_2025_2099_Fig6_HTML" id="d33e2505"/></fig>
</p><p id="Par50">Interestingly, CXCL12-induced migration was significantly increased in S1P<sub>1</sub>-deficient cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>E, F). Since CXCR4 expression levels remained unchanged, this increase likely results from the loss of S1P1&#x02019;s regulatory effect on CXCR4. Consistent with our observation that S1P<sub>1</sub> stimulation further inhibited CXCR4 function in HEK293A cells (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>E), the addition of S1P to the upper chamber reduced KARPAS299 cell migration toward CXCL12 in the lower chamber in control cells, but not in S1P<sub>1</sub>-deficient cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>F). This finding indicates that S1P interferes with CXCL12-induced migration through S1P<sub>1</sub>. In contrast, adding CXCL12 to the upper chamber did not affect S1P-induced migration in KARPAS299 cells (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S6</xref>D), consistent with the unidirectional inhibition of CXCR4 function by S1P<sub>1</sub> observed in HEK293A cells. Additionally, Ex26, at concentration that completely blocks S1P-induced migration, did not alter the CXCL12-induced migration toward the lower chamber (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S6</xref>D, E). This suggests that Ex26 may be insufficient to induce conformational changes in S1P<sub>1</sub> that could impact CXCR4-S1P<sub>1</sub> heteromers. Collectively, these results demonstrate that the S1P/S1P<sub>1</sub> axis attenuates CXCR4 function through the formation of CXCR4-S1P<sub>1</sub> heteromers in KARPAS299 cells.</p><p id="Par51">A previous study showed that FTY720, an agonist and functional inhibitor of S1P<sub>1</sub>, enhanced CXCR4-dependent migration, calcium mobilization, and actin-polymerization in hematopoietic cells in vitro when cells were treated with FTY720 for 3&#x000a0;h [<xref ref-type="bibr" rid="CR47">47</xref>]. To evaluate the effect of FTY720 in KARPAS299 cells, cells were pretreated with or without S1P or FTY720P, the active form of FTY720, for 3&#x000a0;h, and CXCR4-mediated migration was assessed using a transwell migration assay. Both S1P and FTY720P significantly increased CXCL12-induced migration in control cells, while this enhancement was absent in S1P<sub>1</sub>-deficient cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>G), suggesting that the effect depends on S1P<sub>1</sub>. Since S1P<sub>1</sub> agonists are known to induce S1P<sub>1</sub> internalization, the surface expression of S1P<sub>1</sub> was analyzed after 3&#x000a0;h of pretreatment with these agonists. Both S1P and FTY720P substantially decreased surface S1P<sub>1</sub> expression (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>H). Although CXCR4 surface expression was also slightly reduced, possibly due to the co-internalization of CXCR4-S1P<sub>1</sub> heteromers (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>I), CXCL12-induced migration was enhanced, resembling the increase observed in S1P<sub>1</sub>-deficient cells. In summary, these findings indicate that while S1P/S1P<sub>1</sub> axis interferes with CXCR4 function through heteromerization, prolonged treatment of S1P<sub>1</sub> agonists restores CXCR4 function by internalizing S1P<sub>1</sub> from the cell surface.</p><p id="Par52">To further examine the impact of S1P<sub>1</sub> on CXCR4-mediated retention signaling and cell migration in T lymphocytes, we isolated primary T cells from peripheral blood mononuclear cells (PBMCs). Flow cytometry analysis confirmed the isolation of CD4+&#x02009;T cells from PBMCs (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S7</xref>A, B) and revealed uniform expression of CXCR4 in primary T cells (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S7</xref>C). However, the majority of primary T cells did not express S1P<sub>1</sub>, with a small number of cells expressing high and low levels of S1P<sub>1</sub> (Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S7</xref>D), reflecting S1P<sub>1</sub> internalization due to high levels of S1P in peripheral blood [<xref ref-type="bibr" rid="CR86">86</xref>]. Single PLA signals for CXCR4 and S1P<sub>1</sub> were observed in primary T cells at comparable levels (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A), confirming the expression of both receptors in these cells. Double PLA signals were also observed, suggesting the presence of CXCR4-S1P<sub>1</sub> heteromers (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>B). Consistent with the results of CXCR4-mediated cell migration in KARPAS299 cells, stimulation of cells in the upper chamber with S1P interfered with cell migration toward CXCL12, but not with Ex26 (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C). The modulation of CXCR4 by S1P<sub>1</sub> stimulation was less pronounced in primary T cells compared to KARPAS299 cells, probably due to the lack of S1P<sub>1</sub> expression in most T cells. Taken together, these results suggest that S1P<sub>1</sub> forms heteromers with CXCR4 and interferes with CXCR4-mediated cell migration also in primary T cells.</p><p id="Par53">
<fig id="Fig7"><label>Fig. 7</label><caption><p>Presence of CXCR4-S1P<sub>1</sub> heteromers and inhibition of CXCR4-mediated migration by S1P/S1P<sub>1</sub> axis in primary T cells. (<bold>A</bold>) Detection of CXCR4 and S1P<sub>1</sub> homomers in primary T cells. Cells were stained with anti-CXCR4 (Ulocuplumab) or anti-S1P<sub>1</sub> (#218713) antibody alone for probe 1 and 2. (<bold>B</bold>) Detection of CXCR4-S1P<sub>1</sub> heteromers in primary T cells. Cells were stained with human IgG control antibody for probe 1 and 2 (left), anti-CXCR4 for probe 1 and anti-S1P<sub>1</sub> for probe 2 (middle), and anti-S1P<sub>1</sub> for probe 1 and anti-CXCR4 for probe 2 (right). Images are representative of three independent experiments. Scale bars: 10&#x000a0;&#x003bc;m. (<bold>C</bold>) The effect of S1P (10 nM) and S1P<sub>1</sub> antagonist Ex26 (10 &#x000b5;M) on CXCL12 (30 nM)-induced migration was measured in primary T cells. Data represent the mean&#x02009;&#x000b1;&#x02009;SEM of <italic>n</italic>&#x02009;=&#x02009;3 to 5 independent experiments. Statistical significance was tested using two-tailed Student&#x02019;s <italic>t</italic>-test (<bold>A</bold>) and one-way ANOVA followed by Dunnett&#x02019;s post-hoc test (<bold>B</bold>, <bold>C</bold>). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; ns, not significant</p></caption><graphic xlink:href="12964_2025_2099_Fig7_HTML" id="d33e2688"/></fig>
</p></sec></sec><sec id="Sec26"><title>Discussion</title><p id="Par54">In this study, we identified and validated the heteromerization between CXCR4 and S1P<sub>1</sub> using BiFC, BRET, and PLAs in HEK293A, KARPAS299, and primary T cells. Our findings demonstrated that the S1P/S1P<sub>1</sub> axis interferes with CXCR4-mediated G&#x003b1;<sub>i</sub> activation, cAMP responses, calcium signaling, and migration without altering CXCR4 surface expression or its binding to CXCL12. Conversely, CXCL12/CXCR4 did not affect S1P<sub>1</sub>-mediated functions. This modulatory effect of S1P<sub>1</sub> on CXCR4 is mediated by sequestering G proteins away from CXCR4 and reducing CXCR4 oligomerization, with S1P<sub>1</sub>&#x02019;s TM3 domain being essential for this regulation. Furthermore, pretreatment with FTY720P enhanced CXCL12-induced migration by reducing the surface expression of S1P<sub>1</sub>.</p><p id="Par55">Using quantitative BRET, we observed reduced affinity between CXCR4 protomers and decreased oligomerization in the presence of S1P<sub>1</sub> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>E). CXCR4 exists as a mixture of monomers, dimers and oligomers, with its homomerization closely linked to signaling activity. Studies have demonstrated that increased CXCR4 expression enhances oligomerization and basal activity in immune and cancer cells [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Additionally, CXCR4 interacts with other GPCRs and cell surface molecules, including CCR2, CCR5, CXCR7, and CD4, and its function is regulated by these heteromerization [<xref ref-type="bibr" rid="CR36">36</xref>]. CXCL12 stimulation further promotes CXCR4 dimerization and oligomerization, whereas perturbations such as pertussis toxin treatment or TM6 mutations attenuate CXCR4 activity and oligomerization [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Notably, CXCR4 homomerization occurs prior to G protein activation in response to CXCL12 stimulation [<xref ref-type="bibr" rid="CR87">87</xref>]. Importantly, disruption of CXCR4 oligomers has been shown to impair cell migration and pro-survival signaling while sensitizing malignant cells to therapeutic agents such as venetoclax, a Bcl-2 inhibitor [<xref ref-type="bibr" rid="CR88">88</xref>]. These findings collectively suggest that CXCR4 oligomers are more effective in mediating signaling than monomers and reinforce the conclusion that S1P<sub>1</sub> negatively regulates CXCR4 signaling and function by inhibiting CXCR4 oligomerization.</p><p id="Par56">&#x003b2;-Arrestins play a key role in GPCR desensitization and compete with G proteins for GPCR binding [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Several studies have reported &#x003b2;-arrestin cross-recruitment regulated by GPCR heteromerization. For example, angiotensin type 1&#x000a0;A receptor activation enhances &#x003b2;-arrestin interaction with the &#x003b2;2AR [<xref ref-type="bibr" rid="CR74">74</xref>], and LPA<sub>1</sub> activation induces &#x003b2;-arrestin recruitment to S1P<sub>1</sub>, thereby impairing S1P<sub>1</sub>/G&#x003b1;<sub>i</sub> signaling in endothelial junctions [<xref ref-type="bibr" rid="CR17">17</xref>]. In our study, we observed increased interaction between CXCR4 and &#x003b2;-arrestins, as well as &#x003b2;-arrestin cross-recruitment to CXCR4 in the presence of S1P<sub>1</sub> (see Additional file 1: Fig. <xref rid="MOESM1" ref-type="media">S4</xref>A, B). Despite these interactions, CXCR4-mediated G&#x003b1;<sub>i2</sub> activation and recruitment were still interfered by the S1P/S1P<sub>1</sub> axis, even in &#x003b2;-arrestin1/2-deficient HEK293A cells (see Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C, D). These findings suggest that S1P<sub>1</sub> directly modulates CXCR4 function through heteromer formation. CXCR4 has been shown to form high-order oligomers, or nanoclusters, which are essential for its full activation in T cells and cancer cells [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Our results demonstrated that S1P<sub>1</sub> decreases CXCR4-G&#x003b1;<sub>i</sub> pre-association and reduces CXCR4 oligomerization by reducing the affinity between CXCR4 protomers (see Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>G and <xref rid="Fig3" ref-type="fig">3</xref>E). Given that previous study suggests CXCR4 homomerization occurs prior to G protein activation [<xref ref-type="bibr" rid="CR87">87</xref>], our findings indicate that S1P<sub>1</sub> may reduce CXCR4-G&#x003b1;<sub>i</sub> pre-association by altering CXCR4 oligomerization.</p><p id="Par57">To define the interaction interface between CXCR4 and S1P<sub>1</sub>, we initially employed synthetic peptides designed to mimic the TM sequences of the two GPCRs [<xref ref-type="bibr" rid="CR91">91</xref>], but these peptides were ineffective under our experimental conditions. Through the construction of domain-swapped mutants, wherein TM3 or TM4 of S1P<sub>1</sub> was replaced with the corresponding TM of S1P<sub>3</sub>, we identified TM3 of S1P<sub>1</sub> as responsible for the modulation of CXCR4 within the heteromer complex. Since S1P<sub>1</sub> forms heteromers with CXCR4 and interferes with CXCR4-mediated G&#x003b1;<sub>i</sub> activation without affecting CXCL12 binding to CXCR4, it is plausible that TM3 of S1P<sub>1</sub> plays a crucial role in disrupting CXCR4 oligomerization and G protein activation. Further studies should focus on elucidating the detailed molecular mechanisms and identifying specific domains or residues responsible for the modulation of CXCR4 by S1P<sub>1</sub>.</p><p id="Par58">Previous studies have shown that &#x003b2;2ARs expressed on lymphocytes enhance CXCR4-mediated retention signals by forming heteromers, thereby promoting lymphocyte retention in LNs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In contrast, other studies have demonstrated that S1P<sub>1</sub> counteracts CXCR4-mediated retention signals, facilitating the egress of HSPCs from the BM toward the S1P gradient [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. In this context, immune cell egress from lymphoid organs is influenced by the balance between the retention signal mediated by CXCL12/CXCR4 and the egress-promoting signal driven by S1P/S1P<sub>1</sub>. Our study identifies a direct mechanism of heteromer-based modulation of CXCR4 activation by S1P/S1P<sub>1</sub> in both KARPAS299 T cell lymphoma and primary T cells. These findings unveil an unexplored role for S1P<sub>1</sub>, wherein it not only promotes immune cell migration along the S1P gradient in peripheral blood but also actively disrupts the CXCR4-mediated retention signal through heteromer formation.</p><p id="Par59">S1P<sub>1</sub> has been implicated in various health conditions, including autoimmune diseases, inflammatory diseases, neurodegenerative disorders, and cancers such as breast cancer, pancreatic cancer, and glioblastoma [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. This has spurred the development of several S1P<sub>1</sub>-targeted ligands for therapeutic use. For example, FTY720, a clinically approved prodrug of FTY720P for multiple sclerosis, has shown efficacy in various cancer models [<xref ref-type="bibr" rid="CR96">96</xref>]. Additionally, FTY720 exhibits neuroprotective effects in mouse models of Parkinson&#x02019;s disease, while S1P<sub>1</sub> agonist SEW2871 treatment improves cognitive function in rat models of Alzheimer&#x02019;s disease [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Recent studies suggest a complex interplay between CXCR4 and S1P<sub>1</sub> signaling in conditions such as multiple myeloma, glioblastoma, and neurodegenerative diseases, where CXCR4 is a primary therapeutic target [<xref ref-type="bibr" rid="CR99">99</xref>&#x02013;<xref ref-type="bibr" rid="CR101">101</xref>]. Notably, mice deficient in S1P<sub>1</sub> exhibit impaired HSPC mobilization in response to AMD3100, a CXCR4 antagonist, while FTY720 inhibits HSPC mobilization mediated by CXCR4 antagonists but not by G-CSF [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Furthermore, FTY720 has been reported to enhance CXCR4-dependent migration and BM homing of HSPCs [<xref ref-type="bibr" rid="CR47">47</xref>]. In our study, we demonstrated that S1P interferes with CXCR4-mediated migration when cotreated withCXCL12 by acting through CXCR4-S1P<sub>1</sub> heteromers (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>F). Interestingly, pretreatment with S1P or FTY720P enhanced CXCL12-induced migration of KARPAS299 cells by downregulating surface S1P<sub>1</sub>, thereby alleviating S1P<sub>1</sub>-mediated interference of CXCR4 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>G, H), aligning well with prior reports of reduced HSPC mobilization by FTY720 [<xref ref-type="bibr" rid="CR47">47</xref>]. These findings suggest that G protein-biased S1P<sub>1</sub> agonists, which do not induce S1P<sub>1</sub> internalization, could synergistically enhance HSPC mobilization when used in combination with CXCR4 inhibitors. This dual approach could potentiate CXCR4 inhibition while maintaining responsiveness to the S1P gradient in peripheral blood.</p></sec><sec id="Sec27"><title>Conclusion</title><p id="Par60">Our study demonstrates CXCR4-S1P<sub>1</sub> heteromerization and reveals that the S1P/S1P<sub>1</sub> axis regulates CXCR4 function by interfering with G protein association, reducing oligomerization, and suppressing CXCR4-mediated signaling and migration, without altering surface expression or ligand binding. These findings highlight the critical role of S1P<sub>1</sub> in modulating CXCR4-driven immune cell trafficking and provide valuable insights into its physiological and pathological implications.</p></sec><sec id="Sec28" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12964_2025_2099_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Dr. Jong Min Hong for constructing the &#x003b2;-arrestin1/2-deficient HEK293A cells and Dr. Hee-Jung Choi (Seoul National University) for generously providing the pcDNA3.1-EYFP and pcDNA3.1-Rluc8 vectors. We are also grateful to the members of the Huh lab for helpful comments and discussions.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>H.T.K., J.Y.J., and W.K.H. conceived and designed experiments. H.T.K. performed experiments. H.T.K., J.Y.J., and W.K.H. analyzed data. H.T.K., J.Y.J., and W.K.H. wrote the manuscript. All authors reviewed and commented on the manuscript and approved the final version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by GPCR Therapeutics Inc. and the National Research Foundation of Korea (2020R1A5A1018081).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par61">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par62">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par63">J.Y.J. is an employee of GPCR Therapeutics Inc. W.K.H. is a shareholder in GPCR Therapeutics Inc. H.T.K. declares no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>BRET</term><def><p id="Par64">bioluminescence resonance energy transfer</p></def></def-item><def-item><term>BM</term><def><p id="Par65">bone marrow</p></def></def-item><def-item><term>CXCR4</term><def><p id="Par66">C-X-C chemokine receptor type 4</p></def></def-item><def-item><term>D2R</term><def><p id="Par67">dopamine receptor D2</p></def></def-item><def-item><term>DMEM</term><def><p id="Par68">Dulbecco&#x02019;s modified Eagle&#x02019;s medium</p></def></def-item><def-item><term>FBS fetal</term><def><p id="Par69">bovine serum</p></def></def-item><def-item><term>FTY720P</term><def><p id="Par70">FTY720-phosphate</p></def></def-item><def-item><term>GOI</term><def><p id="Par71">gene of interest</p></def></def-item><def-item><term>GPCRs</term><def><p id="Par72">G protein-coupled receptors</p></def></def-item><def-item><term>HSPCs</term><def><p id="Par73">hematopoietic stem/progenitor cells</p></def></def-item><def-item><term>LN</term><def><p id="Par74">lymph node</p></def></def-item><def-item><term>mCit</term><def><p id="Par75">mCitrine</p></def></def-item><def-item><term>MFI</term><def><p id="Par76">mean fluorescence intensity</p></def></def-item><def-item><term>RPMI</term><def><p id="Par77">Roswell Park Memorial Institute</p></def></def-item><def-item><term>S1P</term><def><p id="Par78">sphingosine-1-phosphate</p></def></def-item><def-item><term>S1P<sub>1</sub></term><def><p id="Par79">S1P receptor type 1</p></def></def-item><def-item><term>SLIC</term><def><p id="Par80">sequence-and ligation-independent cloning</p></def></def-item><def-item><term>TM</term><def><p id="Par81">transmembrane domain</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name></person-group><article-title>The molecular basis of G protein-coupled receptor activation</article-title><source>Annu Rev Biochem</source><year>2018</year><volume>87</volume><fpage>897</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060614-033910</pub-id><pub-id pub-id-type="pmid">29925258</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Weis WI, Kobilka BK. The molecular basis of G protein-coupled receptor activation. Annu Rev Biochem. 2018;87:897&#x02013;919.<pub-id pub-id-type="pmid">29925258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Eichel</surname><given-names>K</given-names></name><name><surname>von Zastrow</surname><given-names>M</given-names></name></person-group><article-title>Subcellular Organization of GPCR Signaling</article-title><source>Trends Pharmacol Sci</source><year>2018</year><volume>39</volume><issue>2</issue><fpage>200</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.11.009</pub-id><pub-id pub-id-type="pmid">29478570</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Eichel K, von Zastrow M. Subcellular Organization of GPCR Signaling. Trends Pharmacol Sci. 2018;39(2):200&#x02013;8.<pub-id pub-id-type="pmid">29478570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Hilger</surname><given-names>D</given-names></name><name><surname>Masureel</surname><given-names>M</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name></person-group><article-title>Structure and dynamics of GPCR signaling complexes</article-title><source>Nat Struct Mol Biol</source><year>2018</year><volume>25</volume><issue>1</issue><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41594-017-0011-7</pub-id><pub-id pub-id-type="pmid">29323277</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Hilger D, Masureel M, Kobilka BK. Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol. 2018;25(1):4&#x02013;12.<pub-id pub-id-type="pmid">29323277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>New insights into modes of GPCR activation</article-title><source>Trends Pharmacol Sci</source><year>2018</year><volume>39</volume><issue>4</issue><fpage>367</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.01.001</pub-id><pub-id pub-id-type="pmid">29395118</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wang W, Qiao Y, Li Z. New insights into modes of GPCR activation. Trends Pharmacol Sci. 2018;39(4):367&#x02013;86.<pub-id pub-id-type="pmid">29395118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Latorraca</surname><given-names>NR</given-names></name><name><surname>Venkatakrishnan</surname><given-names>AJ</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name></person-group><article-title>GPCR dynamics: structures in motion</article-title><source>Chem Rev</source><year>2017</year><volume>117</volume><issue>1</issue><fpage>139</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.6b00177</pub-id><pub-id pub-id-type="pmid">27622975</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Latorraca NR, Venkatakrishnan AJ, Dror RO. GPCR dynamics: structures in motion. Chem Rev. 2017;117(1):139&#x02013;55.<pub-id pub-id-type="pmid">27622975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Masuho</surname><given-names>I</given-names></name><name><surname>Skamangas</surname><given-names>NK</given-names></name><name><surname>Muntean</surname><given-names>BS</given-names></name><name><surname>Martemyanov</surname><given-names>KA</given-names></name></person-group><article-title>Diversity of the G&#x003b2;&#x003b3; complexes defines spatial and temporal bias of GPCR signaling</article-title><source>Cell Syst</source><year>2021</year><volume>12</volume><issue>4</issue><fpage>324</fpage><lpage>e375</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2021.02.001</pub-id><pub-id pub-id-type="pmid">33667409</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Masuho I, Skamangas NK, Muntean BS, Martemyanov KA. Diversity of the G&#x003b2;&#x003b3; complexes defines spatial and temporal bias of GPCR signaling. Cell Syst. 2021;12(4):324&#x02013;e375.<pub-id pub-id-type="pmid">33667409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Kamps</surname><given-names>AR</given-names></name><name><surname>Coffman</surname><given-names>CR</given-names></name></person-group><article-title>G protein-coupled receptor roles in cell migration and cell death decisions</article-title><source>Ann N Y Acad Sci</source><year>2005</year><volume>1049</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1196/annals.1334.003</pub-id><pub-id pub-id-type="pmid">15965103</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Kamps AR, Coffman CR. G protein-coupled receptor roles in cell migration and cell death decisions. Ann N Y Acad Sci. 2005;1049:17&#x02013;23.<pub-id pub-id-type="pmid">15965103</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Cotton</surname><given-names>M</given-names></name><name><surname>Claing</surname><given-names>A</given-names></name></person-group><article-title>G protein-coupled receptors stimulation and the control of cell migration</article-title><source>Cell Signal</source><year>2009</year><volume>21</volume><issue>7</issue><fpage>1045</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2009.02.008</pub-id><pub-id pub-id-type="pmid">19249352</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Cotton M, Claing A. G protein-coupled receptors stimulation and the control of cell migration. Cell Signal. 2009;21(7):1045&#x02013;53.<pub-id pub-id-type="pmid">19249352</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Rajagopal</surname><given-names>S</given-names></name><name><surname>Zhai</surname><given-names>B</given-names></name><name><surname>Villen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR)</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><issue>34</issue><fpage>15299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1073/pnas.1008461107</pub-id><pub-id pub-id-type="pmid">20686112</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villen J, et al. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A. 2010;107(34):15299&#x02013;304.<pub-id pub-id-type="pmid">20686112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Gurevich</surname><given-names>VV</given-names></name><name><surname>Gurevich</surname><given-names>EV</given-names></name></person-group><article-title>Overview of different mechanisms of arrestin-mediated signaling</article-title><source>Curr Protoc Pharmacol</source><year>2014</year><volume>67</volume><issue>1</issue><fpage>2</fpage><pub-id pub-id-type="doi">10.1002/0471141755.ph0210s67</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Gurevich VV, Gurevich EV. Overview of different mechanisms of arrestin-mediated signaling. Curr Protoc Pharmacol. 2014;67(1):2.</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>ARB</given-names></name><name><surname>Plouffe</surname><given-names>B</given-names></name><name><surname>Cahill</surname><given-names>TJ</given-names></name><name><surname>Shukla</surname><given-names>AK</given-names></name><name><surname>Tarrasch</surname><given-names>JT</given-names></name><name><surname>Dosey</surname><given-names>AM</given-names></name><etal/></person-group><article-title>GPCR-G Protein-&#x003b2;-Arrestin Super-complex mediates sustained G protein signaling</article-title><source>Cell</source><year>2016</year><volume>166</volume><issue>4</issue><fpage>907</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.004</pub-id><pub-id pub-id-type="pmid">27499021</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Thomsen ARB, Plouffe B, Cahill TJ 3rd, Shukla AK, Tarrasch JT, Dosey AM, et al. GPCR-G Protein-&#x003b2;-Arrestin Super-complex mediates sustained G protein signaling. Cell. 2016;166(4):907&#x02013;19.<pub-id pub-id-type="pmid">27499021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Cahill</surname><given-names>TJ</given-names></name><name><surname>Thomsen</surname><given-names>AR</given-names></name><name><surname>Tarrasch</surname><given-names>JT</given-names></name><name><surname>Plouffe</surname><given-names>B</given-names></name><name><surname>Nguyen</surname><given-names>AH</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Distinct conformations of GPCR-beta-arrestin complexes mediate desensitization, signaling, and endocytosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><issue>10</issue><fpage>2562</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.1701529114</pub-id><pub-id pub-id-type="pmid">28223524</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Cahill TJ 3rd, Thomsen AR, Tarrasch JT, Plouffe B, Nguyen AH, Yang F, et al. Distinct conformations of GPCR-beta-arrestin complexes mediate desensitization, signaling, and endocytosis. Proc Natl Acad Sci U S A. 2017;114(10):2562&#x02013;7.<pub-id pub-id-type="pmid">28223524</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol. 2007;(69):483&#x02013;510.</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>AS</given-names></name><name><surname>Attwood</surname><given-names>MM</given-names></name><name><surname>Rask-Andersen</surname><given-names>M</given-names></name><name><surname>Schi&#x000f6;th</surname><given-names>HB</given-names></name><name><surname>Gloriam</surname><given-names>DE</given-names></name></person-group><article-title>Trends in GPCR drug discovery: new agents, targets and indications</article-title><source>Nat Rev Drug Discov</source><year>2017</year><volume>16</volume><issue>12</issue><fpage>829</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.178</pub-id><pub-id pub-id-type="pmid">29075003</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Hauser AS, Attwood MM, Rask-Andersen M, Schi&#x000f6;th HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16(12):829&#x02013;42.<pub-id pub-id-type="pmid">29075003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>I</given-names></name><name><surname>Ayoub</surname><given-names>MA</given-names></name><name><surname>Fujita</surname><given-names>W</given-names></name><name><surname>Jaeger</surname><given-names>WC</given-names></name><name><surname>Pfleger</surname><given-names>KD</given-names></name><name><surname>Devi</surname><given-names>LA</given-names></name></person-group><article-title>G protein-coupled receptor heteromers</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2016</year><volume>56</volume><fpage>403</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011613-135952</pub-id><pub-id pub-id-type="pmid">26514203</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Gomes I, Ayoub MA, Fujita W, Jaeger WC, Pfleger KD, Devi LA. G protein-coupled receptor heteromers. Annu Rev Pharmacol Toxicol. 2016;56:403&#x02013;25.<pub-id pub-id-type="pmid">26514203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>A</given-names></name><name><surname>Hayano</surname><given-names>Y</given-names></name><name><surname>Furuta</surname><given-names>F</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name></person-group><article-title>Control of lymphocyte egress from lymph nodes through &#x003b2;2-adrenergic receptors</article-title><source>J Exp Med</source><year>2014</year><volume>211</volume><issue>13</issue><fpage>2583</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1084/jem.20141132</pub-id><pub-id pub-id-type="pmid">25422496</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Nakai A, Hayano Y, Furuta F, Noda M, Suzuki K. Control of lymphocyte egress from lymph nodes through &#x003b2;2-adrenergic receptors. J Exp Med. 2014;211(13):2583&#x02013;98.<pub-id pub-id-type="pmid">25422496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Hisano</surname><given-names>Y</given-names></name><name><surname>Kono</surname><given-names>M</given-names></name><name><surname>Cartier</surname><given-names>A</given-names></name><name><surname>Engelbrecht</surname><given-names>E</given-names></name><name><surname>Kano</surname><given-names>K</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name><etal/></person-group><article-title>Lysolipid receptor cross-talk regulates lymphatic endothelial junctions in lymph nodes</article-title><source>J Exp Med</source><year>2019</year><volume>216</volume><issue>7</issue><fpage>1582</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1084/jem.20181895</pub-id><pub-id pub-id-type="pmid">31147448</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hisano Y, Kono M, Cartier A, Engelbrecht E, Kano K, Kawakami K, et al. Lysolipid receptor cross-talk regulates lymphatic endothelial junctions in lymph nodes. J Exp Med. 2019;216(7):1582&#x02013;98.<pub-id pub-id-type="pmid">31147448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Seghiri</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>PK</given-names></name><name><surname>Seo</surname><given-names>HG</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Jo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The beta2-adrenergic receptor associates with CXCR4 multimers in human cancer cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2024</year><volume>121</volume><issue>14</issue><fpage>e2304897121</fpage><pub-id pub-id-type="doi">10.1073/pnas.2304897121</pub-id><pub-id pub-id-type="pmid">38547061</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liang J, Seghiri M, Singh PK, Seo HG, Lee JY, Jo Y, et al. The beta2-adrenergic receptor associates with CXCR4 multimers in human cancer cells. Proc Natl Acad Sci U S A. 2024;121(14):e2304897121.<pub-id pub-id-type="pmid">38547061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Sukhtankar</surname><given-names>DD</given-names></name><name><surname>Fung</surname><given-names>JJ</given-names></name><name><surname>Kim</surname><given-names>M-n</given-names></name><name><surname>Cayton</surname><given-names>T</given-names></name><name><surname>Chiou</surname><given-names>V</given-names></name><name><surname>Caculitan</surname><given-names>NG</given-names></name><etal/></person-group><article-title>GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><issue>10</issue><fpage>e0287863</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0287863</pub-id><pub-id pub-id-type="pmid">37878624</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Sukhtankar DD, Fung JJ, Kim M-n, Cayton T, Chiou V, Caculitan NG, et al. GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol. PLoS ONE. 2023;18(10):e0287863.<pub-id pub-id-type="pmid">37878624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>J-W</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Seen</surname><given-names>D-S</given-names></name><name><surname>Jeong</surname><given-names>J-Y</given-names></name><name><surname>Huh</surname><given-names>W-K</given-names></name></person-group><article-title>Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>1894</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-28531-1</pub-id><pub-id pub-id-type="pmid">36732336</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Park C, Lee J-W, Kim K, Seen D-S, Jeong J-Y, Huh W-K. Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration. Sci Rep. 2023;13(1):1894.<pub-id pub-id-type="pmid">36732336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Seen</surname><given-names>DS</given-names></name><name><surname>Jeong</surname><given-names>JY</given-names></name><name><surname>Huh</surname><given-names>WK</given-names></name></person-group><article-title>LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration</article-title><source>Cell Commun Signal</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>257</fpage><pub-id pub-id-type="doi">10.1186/s12964-023-01261-7</pub-id><pub-id pub-id-type="pmid">37749552</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Hong JM, Lee JW, Seen DS, Jeong JY, Huh WK. LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration. Cell Commun Signal. 2023;21(1):257.<pub-id pub-id-type="pmid">37749552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>DE</given-names></name><name><surname>Bowman</surname><given-names>EP</given-names></name><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><article-title>Hematopoietic stem cells are uniquely selective in their migratory response to Chemokines</article-title><source>J Exp Med</source><year>2002</year><volume>195</volume><issue>9</issue><fpage>1145</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1084/jem.20011284</pub-id><pub-id pub-id-type="pmid">11994419</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to Chemokines. J Exp Med. 2002;195(9):1145&#x02013;54.<pub-id pub-id-type="pmid">11994419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Busillo</surname><given-names>JM</given-names></name><name><surname>Benovic</surname><given-names>JL</given-names></name></person-group><article-title>Regulation of CXCR4 signaling</article-title><source>BBA-Biomembranes</source><year>2007</year><volume>1768</volume><issue>4</issue><fpage>952</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2006.11.002</pub-id><pub-id pub-id-type="pmid">17169327</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Busillo JM, Benovic JL. Regulation of CXCR4 signaling. BBA-Biomembranes. 2007;1768(4):952&#x02013;63.<pub-id pub-id-type="pmid">17169327</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>A</given-names></name><name><surname>Leach</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name></person-group><article-title>Control of immune cell trafficking through inter-organ communication</article-title><source>Int Immunol</source><year>2021</year><volume>33</volume><issue>6</issue><fpage>327</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxab009</pub-id><pub-id pub-id-type="pmid">33751050</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Nakai A, Leach S, Suzuki K. Control of immune cell trafficking through inter-organ communication. Int Immunol. 2021;33(6):327&#x02013;35.<pub-id pub-id-type="pmid">33751050</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Crees</surname><given-names>ZD</given-names></name><name><surname>Rettig</surname><given-names>MP</given-names></name><name><surname>DiPersio</surname><given-names>JF</given-names></name></person-group><article-title>Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide</article-title><source>Ther Adv Hematol</source><year>2023</year><volume>14</volume><fpage>20406207231174304</fpage><pub-id pub-id-type="doi">10.1177/20406207231174304</pub-id><pub-id pub-id-type="pmid">37250913</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Crees ZD, Rettig MP, DiPersio JF. Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol. 2023;14:20406207231174304.<pub-id pub-id-type="pmid">37250913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Liekens</surname><given-names>S</given-names></name><name><surname>Schols</surname><given-names>D</given-names></name><name><surname>Hatse</surname><given-names>S</given-names></name></person-group><article-title>CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization</article-title><source>Curr Pharm Des</source><year>2010</year><volume>16</volume><issue>35</issue><fpage>3903</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.2174/138161210794455003</pub-id><pub-id pub-id-type="pmid">21158728</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Liekens S, Schols D, Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des. 2010;16(35):3903&#x02013;20.<pub-id pub-id-type="pmid">21158728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Badolato</surname><given-names>R</given-names></name><name><surname>Alsina</surname><given-names>L</given-names></name><name><surname>Azar</surname><given-names>A</given-names></name><name><surname>Bertrand</surname><given-names>Y</given-names></name><name><surname>Bolyard</surname><given-names>AA</given-names></name><name><surname>Dale</surname><given-names>D</given-names></name><etal/></person-group><article-title>A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome</article-title><source>Blood</source><year>2024</year><volume>144</volume><issue>1</issue><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1182/blood.2023022658</pub-id><pub-id pub-id-type="pmid">38643510</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Badolato R, Alsina L, Azar A, Bertrand Y, Bolyard AA, Dale D, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35&#x02013;45.<pub-id pub-id-type="pmid">38643510</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name></person-group><article-title>Adrenergic control of lymphocyte trafficking and adaptive immune responses</article-title><source>Neurochem Int</source><year>2019</year><volume>130</volume><fpage>104320</fpage><pub-id pub-id-type="doi">10.1016/j.neuint.2018.10.017</pub-id><pub-id pub-id-type="pmid">30342959</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Nakai A, Suzuki K. Adrenergic control of lymphocyte trafficking and adaptive immune responses. Neurochem Int. 2019;130:104320.<pub-id pub-id-type="pmid">30342959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Elsner</surname><given-names>RA</given-names></name><name><surname>Ernst</surname><given-names>DN</given-names></name><name><surname>Baumgarth</surname><given-names>N</given-names></name></person-group><article-title>Single and coexpression of CXCR4 and CXCR5 identifies CD4 T helper cells in distinct lymph node niches during influenza virus infection</article-title><source>J Virol</source><year>2012</year><volume>86</volume><issue>13</issue><fpage>7146</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1128/JVI.06904-11</pub-id><pub-id pub-id-type="pmid">22532671</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Elsner RA, Ernst DN, Baumgarth N. Single and coexpression of CXCR4 and CXCR5 identifies CD4 T helper cells in distinct lymph node niches during influenza virus infection. J Virol. 2012;86(13):7146&#x02013;57.<pub-id pub-id-type="pmid">22532671</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Behnam Azad</surname><given-names>B</given-names></name><name><surname>Nimmagadda</surname><given-names>S</given-names></name></person-group><article-title>The intricate role of CXCR4 in cancer</article-title><source>Adv Cancer Res</source><year>2014</year><volume>124</volume><fpage>31</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-411638-2.00002-1</pub-id><pub-id pub-id-type="pmid">25287686</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31&#x02013;82.<pub-id pub-id-type="pmid">25287686</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Feig</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>JO</given-names></name><name><surname>Kraman</surname><given-names>M</given-names></name><name><surname>Wells</surname><given-names>RJ</given-names></name><name><surname>Deonarine</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><issue>50</issue><fpage>20212</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320318110</pub-id><pub-id pub-id-type="pmid">24277834</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212&#x02013;7.<pub-id pub-id-type="pmid">24277834</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Bockorny</surname><given-names>B</given-names></name><name><surname>Semenisty</surname><given-names>V</given-names></name><name><surname>Macarulla</surname><given-names>T</given-names></name><name><surname>Borazanci</surname><given-names>E</given-names></name><name><surname>Wolpin</surname><given-names>BM</given-names></name><name><surname>Stemmer</surname><given-names>SM</given-names></name><etal/></person-group><article-title>BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>6</issue><fpage>878</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0880-x</pub-id><pub-id pub-id-type="pmid">32451495</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878&#x02013;85.<pub-id pub-id-type="pmid">32451495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Biasci</surname><given-names>D</given-names></name><name><surname>Smoragiewicz</surname><given-names>M</given-names></name><name><surname>Connell</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Thaventhiran</surname><given-names>JED</given-names></name><etal/></person-group><article-title>CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><issue>46</issue><fpage>28960</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1073/pnas.2013644117</pub-id><pub-id pub-id-type="pmid">33127761</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci U S A. 2020;117(46):28960&#x02013;70.<pub-id pub-id-type="pmid">33127761</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Munoz</surname><given-names>L</given-names></name><name><surname>Rodriguez-Frade</surname><given-names>JM</given-names></name><name><surname>Barroso</surname><given-names>R</given-names></name><name><surname>Sorzano</surname><given-names>COS</given-names></name><name><surname>Torreno-Pina</surname><given-names>JA</given-names></name><name><surname>Santiago</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Separating actin-dependent chemokine receptor nanoclustering from Dimerization indicates a role for clustering in CXCR4 signaling and function</article-title><source>Mol Cell</source><year>2018</year><volume>70</volume><issue>1</issue><fpage>106</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.02.034</pub-id><pub-id pub-id-type="pmid">29625032</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Martinez-Munoz L, Rodriguez-Frade JM, Barroso R, Sorzano COS, Torreno-Pina JA, Santiago CA, et al. Separating actin-dependent chemokine receptor nanoclustering from Dimerization indicates a role for clustering in CXCR4 signaling and function. Mol Cell. 2018;70(1):106&#x02013;19. e10.<pub-id pub-id-type="pmid">29625032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Isbilir</surname><given-names>A</given-names></name><name><surname>Moller</surname><given-names>J</given-names></name><name><surname>Arimont</surname><given-names>M</given-names></name><name><surname>Bobkov</surname><given-names>V</given-names></name><name><surname>Perpina-Viciano</surname><given-names>C</given-names></name><name><surname>Hoffmann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><issue>46</issue><fpage>29144</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1073/pnas.2013319117</pub-id><pub-id pub-id-type="pmid">33148803</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Isbilir A, Moller J, Arimont M, Bobkov V, Perpina-Viciano C, Hoffmann C, et al. Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists. Proc Natl Acad Sci U S A. 2020;117(46):29144&#x02013;54.<pub-id pub-id-type="pmid">33148803</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Sohy</surname><given-names>D</given-names></name><name><surname>Yano</surname><given-names>H</given-names></name><name><surname>de Nadai</surname><given-names>P</given-names></name><name><surname>Urizar</surname><given-names>E</given-names></name><name><surname>Guillabert</surname><given-names>A</given-names></name><name><surname>Javitch</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of selective antagonists</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><issue>45</issue><fpage>31270</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.054809</pub-id><pub-id pub-id-type="pmid">19758998</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Sohy D, Yano H, de Nadai P, Urizar E, Guillabert A, Javitch JA, et al. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of selective antagonists. J Biol Chem. 2009;284(45):31270&#x02013;9.<pub-id pub-id-type="pmid">19758998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Proia</surname><given-names>RL</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><article-title>Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><issue>4</issue><fpage>1379</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1172/JCI76369</pub-id><pub-id pub-id-type="pmid">25831442</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125(4):1379&#x02013;87.<pub-id pub-id-type="pmid">25831442</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Allende</surname><given-names>ML</given-names></name><name><surname>Dreier</surname><given-names>JL</given-names></name><name><surname>Mandala</surname><given-names>S</given-names></name><name><surname>Proia</surname><given-names>RL</given-names></name></person-group><article-title>Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><issue>15</issue><fpage>15396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1074/jbc.M314291200</pub-id><pub-id pub-id-type="pmid">14732704</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem. 2004;279(15):15396&#x02013;401.<pub-id pub-id-type="pmid">14732704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Regard</surname><given-names>JB</given-names></name><name><surname>Sato</surname><given-names>IT</given-names></name><name><surname>Coughlin</surname><given-names>SR</given-names></name></person-group><article-title>Anatomical profiling of G protein-coupled receptor expression</article-title><source>Cell</source><year>2008</year><volume>135</volume><issue>3</issue><fpage>561</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.08.040</pub-id><pub-id pub-id-type="pmid">18984166</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Regard JB, Sato IT, Coughlin SR. Anatomical profiling of G protein-coupled receptor expression. Cell. 2008;135(3):561&#x02013;71.<pub-id pub-id-type="pmid">18984166</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Matloubian</surname><given-names>M</given-names></name><name><surname>Lo</surname><given-names>CG</given-names></name><name><surname>Cinamon</surname><given-names>G</given-names></name><name><surname>Lesneski</surname><given-names>MJ</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Brinkmann</surname><given-names>V</given-names></name><etal/></person-group><article-title>Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1</article-title><source>Nature</source><year>2004</year><volume>427</volume><issue>6972</issue><fpage>355</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nature02284</pub-id><pub-id pub-id-type="pmid">14737169</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355&#x02013;60.<pub-id pub-id-type="pmid">14737169</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>TH</given-names></name><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Matloubian</surname><given-names>M</given-names></name><name><surname>Lo</surname><given-names>CG</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><article-title>S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress</article-title><source>Immunity</source><year>2008</year><volume>28</volume><issue>1</issue><fpage>122</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.11.017</pub-id><pub-id pub-id-type="pmid">18164221</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity. 2008;28(1):122&#x02013;33.<pub-id pub-id-type="pmid">18164221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>J</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name></person-group><article-title>Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis</article-title><source>Clin Neuropharmacol</source><year>2010</year><volume>33</volume><issue>2</issue><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e3181cbf825</pub-id><pub-id pub-id-type="pmid">20061941</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91&#x02013;101.<pub-id pub-id-type="pmid">20061941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y-N</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>T-T</given-names></name><name><surname>Huang</surname><given-names>D-J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sphingosine 1 phosphate receptor-1 (S1P1) promotes tumor-associated regulatory T cell expansion: leading to poor survival in bladder cancer</article-title><source>Cell Death Dis</source><year>2019</year><volume>10</volume><issue>2</issue><fpage>50</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-1298-y</pub-id><pub-id pub-id-type="pmid">30718502</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Liu Y-N, Zhang H, Zhang L, Cai T-T, Huang D-J, He J, et al. Sphingosine 1 phosphate receptor-1 (S1P1) promotes tumor-associated regulatory T cell expansion: leading to poor survival in bladder cancer. Cell Death Dis. 2019;10(2):50.<pub-id pub-id-type="pmid">30718502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Priceman Saul</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Yue</surname><given-names>C</given-names></name><name><surname>Kujawski</surname><given-names>M</given-names></name><etal/></person-group><article-title>S1PR1 is Crucial for Accumulation of Regulatory T Cells in tumors via STAT3</article-title><source>Cell Rep</source><year>2014</year><volume>6</volume><issue>6</issue><fpage>992</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.02.016</pub-id><pub-id pub-id-type="pmid">24630990</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Priceman Saul J, Shen S, Wang L, Deng J, Yue C, Kujawski M, et al. S1PR1 is Crucial for Accumulation of Regulatory T Cells in tumors via STAT3. Cell Rep. 2014;6(6):992&#x02013;9.<pub-id pub-id-type="pmid">24630990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Juarez</surname><given-names>JG</given-names></name><name><surname>Harun</surname><given-names>N</given-names></name><name><surname>Thien</surname><given-names>M</given-names></name><name><surname>Welschinger</surname><given-names>R</given-names></name><name><surname>Baraz</surname><given-names>R</given-names></name><name><surname>Dela Pena</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice</article-title><source>Blood</source><year>2012</year><volume>119</volume><issue>3</issue><fpage>707</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-04-348904</pub-id><pub-id pub-id-type="pmid">22049516</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Juarez JG, Harun N, Thien M, Welschinger R, Baraz R, Dela Pena A, et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood. 2012;119(3):707&#x02013;16.<pub-id pub-id-type="pmid">22049516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Ratajczak MZ, Lee H, Wysoczynski M, Wan W, Marlicz W, Laughlin MJ et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia. 2010;24(5):976&#x02013;&#x02009;85.</mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Boehmler</surname><given-names>AM</given-names></name><name><surname>Seitz</surname><given-names>G</given-names></name><name><surname>Kuci</surname><given-names>S</given-names></name><name><surname>Wiesner</surname><given-names>T</given-names></name><name><surname>Brinkmann</surname><given-names>V</given-names></name><etal/></person-group><article-title>The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34&#x02009;+&#x02009;progenitor cells</article-title><source>Blood</source><year>2004</year><volume>103</volume><issue>12</issue><fpage>4478</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-03-0875</pub-id><pub-id pub-id-type="pmid">14988150</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Kimura T, Boehmler AM, Seitz G, Kuci S, Wiesner T, Brinkmann V, et al. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34&#x02009;+&#x02009;progenitor cells. Blood. 2004;103(12):4478&#x02013;86.<pub-id pub-id-type="pmid">14988150</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>EW</given-names></name><name><surname>Seen</surname><given-names>DS</given-names></name><name><surname>Song</surname><given-names>YB</given-names></name><name><surname>Son</surname><given-names>HS</given-names></name><name><surname>Jung</surname><given-names>NC</given-names></name><name><surname>Huh</surname><given-names>WK</given-names></name><etal/></person-group><article-title>AdHTS: a high-throughput system for generating recombinant adenoviruses</article-title><source>J Biotechnol</source><year>2012</year><volume>162</volume><issue>2&#x02013;3</issue><fpage>246</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2012.10.001</pub-id><pub-id pub-id-type="pmid">23063969</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Choi EW, Seen DS, Song YB, Son HS, Jung NC, Huh WK, et al. AdHTS: a high-throughput system for generating recombinant adenoviruses. J Biotechnol. 2012;162(2&#x02013;3):246&#x02013;52.<pub-id pub-id-type="pmid">23063969</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>YB</given-names></name><name><surname>Park</surname><given-names>CO</given-names></name><name><surname>Jeong</surname><given-names>JY</given-names></name><name><surname>Huh</surname><given-names>WK</given-names></name></person-group><article-title>Monitoring G protein-coupled receptor activation using an adenovirus-based &#x003b2;-arrestin bimolecular fluorescence complementation assay</article-title><source>Anal Biochem</source><year>2014</year><volume>449</volume><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2013.12.017</pub-id><pub-id pub-id-type="pmid">24361713</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Song YB, Park CO, Jeong JY, Huh WK. Monitoring G protein-coupled receptor activation using an adenovirus-based &#x003b2;-arrestin bimolecular fluorescence complementation assay. Anal Biochem. 2014;449:32&#x02013;41.<pub-id pub-id-type="pmid">24361713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>JY</given-names></name><name><surname>Yim</surname><given-names>HS</given-names></name><name><surname>Ryu</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Seen</surname><given-names>DS</given-names></name><etal/></person-group><article-title>One-step sequence- and ligation-independent cloning as a rapid and versatile cloning method for functional genomics studies</article-title><source>Appl Environ Microbiol</source><year>2012</year><volume>78</volume><issue>15</issue><fpage>5440</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1128/AEM.00844-12</pub-id><pub-id pub-id-type="pmid">22610439</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Jeong JY, Yim HS, Ryu JY, Lee HS, Lee JH, Seen DS, et al. One-step sequence- and ligation-independent cloning as a rapid and versatile cloning method for functional genomics studies. Appl Environ Microbiol. 2012;78(15):5440&#x02013;3.<pub-id pub-id-type="pmid">22610439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Beaven</surname><given-names>AH</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ko</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Biophysical and functional characterization of Norrin signaling through Frizzled4</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><issue>35</issue><fpage>8787</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1073/pnas.1805901115</pub-id><pub-id pub-id-type="pmid">30104375</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Bang I, Kim HR, Beaven AH, Kim J, Ko SB, Lee GR, et al. Biophysical and functional characterization of Norrin signaling through Frizzled4. Proc Natl Acad Sci U S A. 2018;115(35):8787&#x02013;92.<pub-id pub-id-type="pmid">30104375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Bankovich</surname><given-names>AJ</given-names></name><name><surname>Shiow</surname><given-names>LR</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><article-title>CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><issue>29</issue><fpage>22328</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.123299</pub-id><pub-id pub-id-type="pmid">20463015</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Bankovich AJ, Shiow LR, Cyster JG. CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4. J Biol Chem. 2010;285(29):22328&#x02013;37.<pub-id pub-id-type="pmid">20463015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>MA</given-names></name><name><surname>Roth</surname><given-names>CB</given-names></name><name><surname>Jo</surname><given-names>E</given-names></name><name><surname>Griffith</surname><given-names>MT</given-names></name><name><surname>Scott</surname><given-names>FL</given-names></name><name><surname>Reinhart</surname><given-names>G</given-names></name><etal/></person-group><article-title>Crystal structure of a lipid G protein-coupled receptor</article-title><source>Science</source><year>2012</year><volume>335</volume><issue>6070</issue><fpage>851</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.1215904</pub-id><pub-id pub-id-type="pmid">22344443</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, et al. Crystal structure of a lipid G protein-coupled receptor. Science. 2012;335(6070):851&#x02013;5.<pub-id pub-id-type="pmid">22344443</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Maeda S, Shiimura Y, Asada H, Hirata K, Luo F, Nango E et al. Endogenous agonist-bound S1PR3 structure reveals determinants of G protein-subtype bias. Sci Adv 2021;7(24).</mixed-citation></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhne</surname><given-names>MR</given-names></name><name><surname>Mulvey</surname><given-names>T</given-names></name><name><surname>Belanger</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Chong</surname><given-names>C</given-names></name><etal/></person-group><article-title>BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><issue>2</issue><fpage>357</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2333</pub-id><pub-id pub-id-type="pmid">23213054</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19(2):357&#x02013;66.<pub-id pub-id-type="pmid">23213054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Cano</surname><given-names>M</given-names></name><name><surname>Fern&#x000e1;ndez-Due&#x000f1;as</surname><given-names>V</given-names></name><name><surname>Ciruela</surname><given-names>F</given-names></name></person-group><article-title>Proximity ligation assay image analysis protocol: addressing receptor-receptor interactions</article-title><source>Methods Mol Biol</source><year>2019</year><volume>2040</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9686-5_3</pub-id><pub-id pub-id-type="pmid">31432474</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">L&#x000f3;pez-Cano M, Fern&#x000e1;ndez-Due&#x000f1;as V, Ciruela F. Proximity ligation assay image analysis protocol: addressing receptor-receptor interactions. Methods Mol Biol. 2019;2040:41&#x02013;50.<pub-id pub-id-type="pmid">31432474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Binkowski</surname><given-names>BF</given-names></name><name><surname>Butler</surname><given-names>BL</given-names></name><name><surname>Stecha</surname><given-names>PF</given-names></name><name><surname>Eggers</surname><given-names>CT</given-names></name><name><surname>Otto</surname><given-names>P</given-names></name><name><surname>Zimmerman</surname><given-names>K</given-names></name><etal/></person-group><article-title>A luminescent biosensor with increased dynamic range for intracellular cAMP</article-title><source>ACS Chem Biol</source><year>2011</year><volume>6</volume><issue>11</issue><fpage>1193</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1021/cb200248h</pub-id><pub-id pub-id-type="pmid">21932825</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Binkowski BF, Butler BL, Stecha PF, Eggers CT, Otto P, Zimmerman K, et al. A luminescent biosensor with increased dynamic range for intracellular cAMP. ACS Chem Biol. 2011;6(11):1193&#x02013;7.<pub-id pub-id-type="pmid">21932825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>RHJ</given-names></name><name><surname>DiBerto</surname><given-names>JF</given-names></name><name><surname>English</surname><given-names>JG</given-names></name><name><surname>Glaudin</surname><given-names>AM</given-names></name><name><surname>Krumm</surname><given-names>BE</given-names></name><name><surname>Slocum</surname><given-names>ST</given-names></name><etal/></person-group><article-title>TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome</article-title><source>Nat Chem Biol</source><year>2020</year><volume>16</volume><issue>8</issue><fpage>841</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-0535-8</pub-id><pub-id pub-id-type="pmid">32367019</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Olsen RHJ, DiBerto JF, English JG, Glaudin AM, Krumm BE, Slocum ST, et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat Chem Biol. 2020;16(8):841&#x02013;9.<pub-id pub-id-type="pmid">32367019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Ayoub</surname><given-names>MA</given-names></name><name><surname>Maurel</surname><given-names>D</given-names></name><name><surname>Binet</surname><given-names>V</given-names></name><name><surname>Fink</surname><given-names>M</given-names></name><name><surname>Pr&#x000e9;zeau</surname><given-names>L</given-names></name><name><surname>Ansanay</surname><given-names>H</given-names></name><etal/></person-group><article-title>Real-time analysis of agonist-induced activation of protease-activated receptor 1/Galphai1 protein complex measured by bioluminescence resonance energy transfer in living cells</article-title><source>Mol Pharmacol</source><year>2007</year><volume>71</volume><issue>5</issue><fpage>1329</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1124/mol.106.030304</pub-id><pub-id pub-id-type="pmid">17267663</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Ayoub MA, Maurel D, Binet V, Fink M, Pr&#x000e9;zeau L, Ansanay H, et al. Real-time analysis of agonist-induced activation of protease-activated receptor 1/Galphai1 protein complex measured by bioluminescence resonance energy transfer in living cells. Mol Pharmacol. 2007;71(5):1329&#x02013;40.<pub-id pub-id-type="pmid">17267663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Armando</surname><given-names>S</given-names></name><name><surname>Quoyer</surname><given-names>J</given-names></name><name><surname>Lukashova</surname><given-names>V</given-names></name><name><surname>Maiga</surname><given-names>A</given-names></name><name><surname>Percherancier</surname><given-names>Y</given-names></name><name><surname>Heveker</surname><given-names>N</given-names></name><etal/></person-group><article-title>The chemokine CXC4 and CC2 receptors form homo- and heterooligomers that can engage their signaling G-protein effectors and &#x003b2;arrestin</article-title><source>Faseb j</source><year>2014</year><volume>28</volume><issue>10</issue><fpage>4509</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1096/fj.13-242446</pub-id><pub-id pub-id-type="pmid">25053617</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Armando S, Quoyer J, Lukashova V, Maiga A, Percherancier Y, Heveker N, et al. The chemokine CXC4 and CC2 receptors form homo- and heterooligomers that can engage their signaling G-protein effectors and &#x003b2;arrestin. Faseb j. 2014;28(10):4509&#x02013;23.<pub-id pub-id-type="pmid">25053617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Gal&#x000e9;s</surname><given-names>C</given-names></name><name><surname>Van Durm</surname><given-names>JJ</given-names></name><name><surname>Schaak</surname><given-names>S</given-names></name><name><surname>Pontier</surname><given-names>S</given-names></name><name><surname>Percherancier</surname><given-names>Y</given-names></name><name><surname>Audet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes</article-title><source>Nat Struct Mol Biol</source><year>2006</year><volume>13</volume><issue>9</issue><fpage>778</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/nsmb1134</pub-id><pub-id pub-id-type="pmid">16906158</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Gal&#x000e9;s C, Van Durm JJ, Schaak S, Pontier S, Percherancier Y, Audet M, et al. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol. 2006;13(9):778&#x02013;86.<pub-id pub-id-type="pmid">16906158</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Duquenne</surname><given-names>C</given-names></name><name><surname>Gimenez</surname><given-names>S</given-names></name><name><surname>Guigues</surname><given-names>A</given-names></name><name><surname>Viala</surname><given-names>B</given-names></name><name><surname>Boulouis</surname><given-names>C</given-names></name><name><surname>Mettling</surname><given-names>C</given-names></name><etal/></person-group><article-title>Reversing HIV latency via sphingosine-1-phosphate receptor 1 signaling</article-title><source>Aids</source><year>2017</year><volume>31</volume><issue>18</issue><fpage>2443</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001649</pub-id><pub-id pub-id-type="pmid">28926402</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Duquenne C, Gimenez S, Guigues A, Viala B, Boulouis C, Mettling C, et al. Reversing HIV latency via sphingosine-1-phosphate receptor 1 signaling. Aids. 2017;31(18):2443&#x02013;54.<pub-id pub-id-type="pmid">28926402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Laboute T, Gand&#x000ed;a J, Pellissier LP, Corde Y, Rebeillard F, Gallo M et al. The orphan receptor GPR88 blunts the signaling of opioid receptors and multiple striatal GPCRs. Elife 2020;9.</mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f6;derberg</surname><given-names>O</given-names></name><name><surname>Leuchowius</surname><given-names>KJ</given-names></name><name><surname>Gullberg</surname><given-names>M</given-names></name><name><surname>Jarvius</surname><given-names>M</given-names></name><name><surname>Weibrecht</surname><given-names>I</given-names></name><name><surname>Larsson</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay</article-title><source>Methods</source><year>2008</year><volume>45</volume><issue>3</issue><fpage>227</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2008.06.014</pub-id><pub-id pub-id-type="pmid">18620061</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">S&#x000f6;derberg O, Leuchowius KJ, Gullberg M, Jarvius M, Weibrecht I, Larsson LG, et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods. 2008;45(3):227&#x02013;32.<pub-id pub-id-type="pmid">18620061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Achour</surname><given-names>L</given-names></name><name><surname>Kamal</surname><given-names>M</given-names></name><name><surname>Jockers</surname><given-names>R</given-names></name><name><surname>Marullo</surname><given-names>S</given-names></name></person-group><article-title>Using quantitative BRET to assess G protein-coupled receptor homo- and heterodimerization</article-title><source>Methods Mol Biol</source><year>2011</year><volume>756</volume><fpage>183</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-160-4_9</pub-id><pub-id pub-id-type="pmid">21870226</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Achour L, Kamal M, Jockers R, Marullo S. Using quantitative BRET to assess G protein-coupled receptor homo- and heterodimerization. Methods Mol Biol. 2011;756:183&#x02013;200.<pub-id pub-id-type="pmid">21870226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Takuwa</surname><given-names>N</given-names></name><name><surname>Gonda</surname><given-names>K</given-names></name><name><surname>Okazaki</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Yatomi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2&#x02009;+&#x02009;mobilization, ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><issue>42</issue><fpage>27104</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.42.27104</pub-id><pub-id pub-id-type="pmid">9765227</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Okamoto H, Takuwa N, Gonda K, Okazaki H, Chang K, Yatomi Y, et al. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2&#x02009;+&#x02009;mobilization, ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem. 1998;273(42):27104&#x02013;10.<pub-id pub-id-type="pmid">9765227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER. Next-generation Charact Cancer Cell Line Encyclopedia Nat. 2019;569(7757):503&#x02013;8. 3rd et al.</mixed-citation></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Ayoub</surname><given-names>MA</given-names></name><name><surname>Al-Senaidy</surname><given-names>A</given-names></name><name><surname>Pin</surname><given-names>JP</given-names></name></person-group><article-title>Receptor-G protein interaction studied by bioluminescence resonance energy transfer: lessons from protease-activated receptor 1</article-title><source>Front Endocrinol (Lausanne)</source><year>2012</year><volume>3</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.3389/fendo.2012.00082</pub-id><pub-id pub-id-type="pmid">22737145</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Ayoub MA, Al-Senaidy A, Pin JP. Receptor-G protein interaction studied by bioluminescence resonance energy transfer: lessons from protease-activated receptor 1. Front Endocrinol (Lausanne). 2012;3:82.<pub-id pub-id-type="pmid">22737145</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>NJ</given-names></name><name><surname>Milligan</surname><given-names>G</given-names></name></person-group><article-title>Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes</article-title><source>Pharmacol Rev</source><year>2010</year><volume>62</volume><issue>4</issue><fpage>701</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1124/pr.110.002667</pub-id><pub-id pub-id-type="pmid">21079041</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Smith NJ, Milligan G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev. 2010;62(4):701&#x02013;25.<pub-id pub-id-type="pmid">21079041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="other">Haack KKV, McCarty NA. Functional Consequences of GPCR Heterodimerization: GPCRs as Allosteric Modulators. Pharmaceuticals. 2011;4(3):509&#x02013;&#x02009;23.</mixed-citation></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">T&#x000f3;th AD, Garger D, Prokop S, Solt&#x000e9;sz-Katona E, V&#x000e1;rnai P, Balla A et al. A general method for quantifying ligand binding to unmodified receptors using Gaussia luciferase. J Biol Chem 2021;296.</mixed-citation></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Rajagopal</surname><given-names>S</given-names></name><name><surname>Shenoy</surname><given-names>SK</given-names></name></person-group><article-title>GPCR desensitization: Acute and prolonged phases</article-title><source>Cell Signal</source><year>2018</year><volume>41</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2017.01.024</pub-id><pub-id pub-id-type="pmid">28137506</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Rajagopal S, Shenoy SK. GPCR desensitization: Acute and prolonged phases. Cell Signal. 2018;41:9&#x02013;16.<pub-id pub-id-type="pmid">28137506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeiffer</surname><given-names>M</given-names></name><name><surname>Koch</surname><given-names>T</given-names></name><name><surname>Schroder</surname><given-names>H</given-names></name><name><surname>Laugsch</surname><given-names>M</given-names></name><name><surname>Hollt</surname><given-names>V</given-names></name><name><surname>Schulz</surname><given-names>S</given-names></name></person-group><article-title>Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>22</issue><fpage>19762</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110373200</pub-id><pub-id pub-id-type="pmid">11896051</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem. 2002;277(22):19762&#x02013;72.<pub-id pub-id-type="pmid">11896051</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Toth</surname><given-names>AD</given-names></name><name><surname>Gyombolai</surname><given-names>P</given-names></name><name><surname>Szalai</surname><given-names>B</given-names></name><name><surname>Varnai</surname><given-names>P</given-names></name><name><surname>Turu</surname><given-names>G</given-names></name><name><surname>Hunyady</surname><given-names>L</given-names></name></person-group><article-title>Angiotensin type 1A receptor regulates beta-arrestin binding of the beta(2)-adrenergic receptor via heterodimerization</article-title><source>Mol Cell Endocrinol</source><year>2017</year><volume>442</volume><fpage>113</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2016.11.027</pub-id><pub-id pub-id-type="pmid">27908837</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Toth AD, Gyombolai P, Szalai B, Varnai P, Turu G, Hunyady L. Angiotensin type 1A receptor regulates beta-arrestin binding of the beta(2)-adrenergic receptor via heterodimerization. Mol Cell Endocrinol. 2017;442:113&#x02013;24.<pub-id pub-id-type="pmid">27908837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Robleto</surname><given-names>VL</given-names></name><name><surname>Zhuo</surname><given-names>Y</given-names></name><name><surname>Crecelius</surname><given-names>JM</given-names></name><name><surname>Benzow</surname><given-names>S</given-names></name><name><surname>Marchese</surname><given-names>A</given-names></name></person-group><article-title>SNX9 family mediates &#x003b2;arrestin-independent GPCR endocytosis</article-title><source>Commun Biology</source><year>2024</year><volume>7</volume><issue>1</issue><fpage>1455</fpage><pub-id pub-id-type="doi">10.1038/s42003-024-07157-7</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Robleto VL, Zhuo Y, Crecelius JM, Benzow S, Marchese A. SNX9 family mediates &#x003b2;arrestin-independent GPCR endocytosis. Commun Biology. 2024;7(1):1455.</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Javitch</surname><given-names>JA</given-names></name></person-group><article-title>The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><issue>7</issue><fpage>4385</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1074/jbc.C200679200</pub-id><pub-id pub-id-type="pmid">12496294</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Guo W, Shi L, Javitch JA. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem. 2003;278(7):4385&#x02013;8.<pub-id pub-id-type="pmid">12496294</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Filizola</surname><given-names>M</given-names></name><name><surname>Weinstein</surname><given-names>H</given-names></name><name><surname>Javitch</surname><given-names>JA</given-names></name></person-group><article-title>Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><issue>48</issue><fpage>17495</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1073/pnas.0508950102</pub-id><pub-id pub-id-type="pmid">16301531</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Guo W, Shi L, Filizola M, Weinstein H, Javitch JA. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci U S A. 2005;102(48):17495&#x02013;500.<pub-id pub-id-type="pmid">16301531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Bueschbell</surname><given-names>B</given-names></name><name><surname>Magalh&#x000e3;es</surname><given-names>PR</given-names></name><name><surname>Barreto</surname><given-names>CAV</given-names></name><name><surname>Melo</surname><given-names>R</given-names></name><name><surname>Schiedel</surname><given-names>AC</given-names></name><name><surname>Machuqueiro</surname><given-names>M</given-names></name><etal/></person-group><article-title>The World of GPCR dimers - mapping dopamine receptor D(2) homodimers in different activation states and configuration arrangements</article-title><source>Comput Struct Biotechnol J</source><year>2023</year><volume>21</volume><fpage>4336</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2023.08.032</pub-id><pub-id pub-id-type="pmid">37711187</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Bueschbell B, Magalh&#x000e3;es PR, Barreto CAV, Melo R, Schiedel AC, Machuqueiro M, et al. The World of GPCR dimers - mapping dopamine receptor D(2) homodimers in different activation states and configuration arrangements. Comput Struct Biotechnol J. 2023;21:4336&#x02013;53.<pub-id pub-id-type="pmid">37711187</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, Spyridopoulos I, Chun J, Brinkmann V, Keul P, et al: Sphingosine-1-Phosphate Stimulates the Functional Capacity of Progenitor Cells by Activation of the CXCR4-Dependent Signaling Pathway via the S1P3 Receptor. Arterioscler Thromb Vasc Biol. 2007;27:275&#x02013;82.</mixed-citation></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Ticchioni</surname><given-names>M</given-names></name><name><surname>Charvet</surname><given-names>C</given-names></name><name><surname>Noraz</surname><given-names>N</given-names></name><name><surname>Lamy</surname><given-names>L</given-names></name><name><surname>Steinberg</surname><given-names>M</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><etal/></person-group><article-title>Signaling through ZAP-70 is required for CXCL12-mediated T-cell transendothelial migration</article-title><source>Blood</source><year>2002</year><volume>99</volume><issue>9</issue><fpage>3111</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1182/blood.V99.9.3111</pub-id><pub-id pub-id-type="pmid">11964272</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Ticchioni M, Charvet C, Noraz N, Lamy L, Steinberg M, Bernard A, et al. Signaling through ZAP-70 is required for CXCL12-mediated T-cell transendothelial migration. Blood. 2002;99(9):3111&#x02013;8.<pub-id pub-id-type="pmid">11964272</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Patrussi</surname><given-names>L</given-names></name><name><surname>Baldari</surname><given-names>CT</given-names></name></person-group><article-title>Intracellular mediators of CXCR4-dependent signaling in T cells</article-title><source>Immunol Lett</source><year>2008</year><volume>115</volume><issue>2</issue><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2007.10.012</pub-id><pub-id pub-id-type="pmid">18054087</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Patrussi L, Baldari CT. Intracellular mediators of CXCR4-dependent signaling in T cells. Immunol Lett. 2008;115(2):75&#x02013;82.<pub-id pub-id-type="pmid">18054087</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Fischer P, Nacheva E, Mason D, Sherrington P, Hoyle C, Hayhoe F et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin&#x02019;s lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988;72(1):234&#x02013;&#x02009;40.</mixed-citation></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>F</given-names></name><name><surname>Dell&#x02019;Agnola</surname><given-names>C</given-names></name><name><surname>Mancuso</surname><given-names>P</given-names></name><name><surname>Rabascio</surname><given-names>C</given-names></name><name><surname>Burlini</surname><given-names>A</given-names></name><name><surname>Monestiroli</surname><given-names>S</given-names></name><etal/></person-group><article-title>CXCR4 neutralization, a Novel Therapeutic Approach for Non-hodgkin&#x02019;s Lymphoma1</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><issue>11</issue><fpage>3106</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12036921</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Bertolini F, Dell&#x02019;Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, et al. CXCR4 neutralization, a Novel Therapeutic Approach for Non-hodgkin&#x02019;s Lymphoma1. Cancer Res. 2002;62(11):3106&#x02013;12.<pub-id pub-id-type="pmid">12036921</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Broussas</surname><given-names>M</given-names></name><name><surname>Boute</surname><given-names>N</given-names></name><name><surname>Akla</surname><given-names>B</given-names></name><name><surname>Berger</surname><given-names>S</given-names></name><name><surname>Beau-Larvor</surname><given-names>C</given-names></name><name><surname>Champion</surname><given-names>T</given-names></name><etal/></person-group><article-title>A new Anti-CXCR4 antibody that blocks the CXCR4/SDF-1 Axis and mobilizes Effector cells</article-title><source>Mol Cancer Ther</source><year>2016</year><volume>15</volume><issue>8</issue><fpage>1890</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0041</pub-id><pub-id pub-id-type="pmid">27297868</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Broussas M, Boute N, Akla B, Berger S, Beau-Larvor C, Champion T, et al. A new Anti-CXCR4 antibody that blocks the CXCR4/SDF-1 Axis and mobilizes Effector cells. Mol Cancer Ther. 2016;15(8):1890&#x02013;9.<pub-id pub-id-type="pmid">27297868</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Weissenbach</surname><given-names>M</given-names></name><name><surname>Clahsen</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Spitzer</surname><given-names>D</given-names></name><name><surname>Wirth</surname><given-names>D</given-names></name><name><surname>Vestweber</surname><given-names>D</given-names></name><etal/></person-group><article-title>Interleukin-6 is a direct mediator of T&#x02004;cell migration</article-title><source>Eur J Immunol</source><year>2004</year><volume>34</volume><issue>10</issue><fpage>2895</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1002/eji.200425237</pub-id><pub-id pub-id-type="pmid">15368306</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Weissenbach M, Clahsen T, Weber C, Spitzer D, Wirth D, Vestweber D, et al. Interleukin-6 is a direct mediator of T&#x02004;cell migration. Eur J Immunol. 2004;34(10):2895&#x02013;906.<pub-id pub-id-type="pmid">15368306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>SR</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><article-title>Finding a way out: lymphocyte egress from lymphoid organs</article-title><source>Nat Immunol</source><year>2007</year><volume>8</volume><issue>12</issue><fpage>1295</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/ni1545</pub-id><pub-id pub-id-type="pmid">18026082</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007;8(12):1295&#x02013;301.<pub-id pub-id-type="pmid">18026082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Perpi&#x000f1;&#x000e1;-Viciano</surname><given-names>C</given-names></name><name><surname>I&#x0015f;bilir</surname><given-names>A</given-names></name><name><surname>Zarca</surname><given-names>A</given-names></name><name><surname>Caspar</surname><given-names>B</given-names></name><name><surname>Kilpatrick</surname><given-names>LE</given-names></name><name><surname>Hill</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Kinetic analysis of the Early Signaling steps of the human chemokine receptor CXCR4</article-title><source>Mol Pharmacol</source><year>2020</year><volume>98</volume><issue>2</issue><fpage>72</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1124/mol.119.118448</pub-id><pub-id pub-id-type="pmid">32474443</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Perpi&#x000f1;&#x000e1;-Viciano C, I&#x0015f;bilir A, Zarca A, Caspar B, Kilpatrick LE, Hill SJ, et al. Kinetic analysis of the Early Signaling steps of the human chemokine receptor CXCR4. Mol Pharmacol. 2020;98(2):72&#x02013;87.<pub-id pub-id-type="pmid">32474443</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="other">Mobach S, Bergkamp ND, Ma Z, Haselager MV, Anbuhl SM, Jurriens D et al. Disruption of basal CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms. bioRxiv 2024:2024.12.06.627249.</mixed-citation></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Defea</surname><given-names>K</given-names></name></person-group><article-title>Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction</article-title><source>Br J Pharmacol</source><year>2008</year><volume>153</volume><issue>Suppl 1</issue><fpage>S298</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">18037927</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Defea K. Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol. 2008;153(Suppl 1):S298&#x02013;309.<pub-id pub-id-type="pmid">18037927</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Jean-Charles</surname><given-names>PY</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Shenoy</surname><given-names>SK</given-names></name></person-group><article-title>G protein-coupled receptor signaling through &#x003b2;-Arrestin-dependent mechanisms</article-title><source>J Cardiovasc Pharmacol</source><year>2017</year><volume>70</volume><issue>3</issue><fpage>142</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1097/FJC.0000000000000482</pub-id><pub-id pub-id-type="pmid">28328745</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Jean-Charles PY, Kaur S, Shenoy SK. G protein-coupled receptor signaling through &#x003b2;-Arrestin-dependent mechanisms. J Cardiovasc Pharmacol. 2017;70(3):142&#x02013;58.<pub-id pub-id-type="pmid">28328745</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>G</given-names></name><name><surname>Cordom&#x000ed;</surname><given-names>A</given-names></name><name><surname>Brugarolas</surname><given-names>M</given-names></name><name><surname>Moreno</surname><given-names>E</given-names></name><name><surname>Aguinaga</surname><given-names>D</given-names></name><name><surname>P&#x000e9;rez-Benito</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cross-communication between G(i) and G(s) in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain</article-title><source>BMC Biol</source><year>2018</year><volume>16</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s12915-018-0491-x</pub-id><pub-id pub-id-type="pmid">29486745</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Navarro G, Cordom&#x000ed; A, Brugarolas M, Moreno E, Aguinaga D, P&#x000e9;rez-Benito L, et al. Cross-communication between G(i) and G(s) in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain. BMC Biol. 2018;16(1):24.<pub-id pub-id-type="pmid">29486745</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Ryser</surname><given-names>MF</given-names></name><name><surname>Ugarte</surname><given-names>F</given-names></name><name><surname>Lehmann</surname><given-names>R</given-names></name><name><surname>Bornhauser</surname><given-names>M</given-names></name><name><surname>Brenner</surname><given-names>S</given-names></name></person-group><article-title>S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34&#x02009;+&#x02009;hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homing</article-title><source>Mol Immunol</source><year>2008</year><volume>46</volume><issue>1</issue><fpage>166</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2008.07.016</pub-id><pub-id pub-id-type="pmid">18760838</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Ryser MF, Ugarte F, Lehmann R, Bornhauser M, Brenner S. S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34&#x02009;+&#x02009;hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homing. Mol Immunol. 2008;46(1):166&#x02013;71.<pub-id pub-id-type="pmid">18760838</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>TH</given-names></name><name><surname>Bannard</surname><given-names>O</given-names></name><name><surname>Gray</surname><given-names>EE</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><article-title>CXCR4 promotes B cell egress from Peyer&#x02019;s patches</article-title><source>J Exp Med</source><year>2013</year><volume>210</volume><issue>6</issue><fpage>1099</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1084/jem.20122574</pub-id><pub-id pub-id-type="pmid">23669394</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Schmidt TH, Bannard O, Gray EE, Cyster JG. CXCR4 promotes B cell egress from Peyer&#x02019;s patches. J Exp Med. 2013;210(6):1099&#x02013;107.<pub-id pub-id-type="pmid">23669394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Rostami</surname><given-names>N</given-names></name><name><surname>Nikkhoo</surname><given-names>A</given-names></name><name><surname>Ajjoolabady</surname><given-names>A</given-names></name><name><surname>Azizi</surname><given-names>G</given-names></name><name><surname>Hojjat-Farsangi</surname><given-names>M</given-names></name><name><surname>Ghalamfarsa</surname><given-names>G</given-names></name><etal/></person-group><article-title>S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy</article-title><source>Mol Diag Ther</source><year>2019</year><volume>23</volume><issue>4</issue><fpage>467</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/s40291-019-00401-5</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Rostami N, Nikkhoo A, Ajjoolabady A, Azizi G, Hojjat-Farsangi M, Ghalamfarsa G, et al. S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy. Mol Diag Ther. 2019;23(4):467&#x02013;87.</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Stepanovska</surname><given-names>B</given-names></name><name><surname>Huwiler</surname><given-names>A</given-names></name></person-group><article-title>Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases</article-title><source>Pharmacol Res</source><year>2020</year><volume>154</volume><fpage>104170</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.02.009</pub-id><pub-id pub-id-type="pmid">30776422</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacol Res. 2020;154:104170.<pub-id pub-id-type="pmid">30776422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>C</given-names></name><name><surname>Alshaker</surname><given-names>H</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Winkler</surname><given-names>M</given-names></name><name><surname>Pchejetski</surname><given-names>D</given-names></name></person-group><article-title>The emerging role of FTY720 (Fingolimod) in cancer treatment</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>17</issue><fpage>23106</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7145</pub-id><pub-id pub-id-type="pmid">27036015</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">White C, Alshaker H, Cooper C, Winkler M, Pchejetski D. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget. 2016;7(17):23106&#x02013;27.<pub-id pub-id-type="pmid">27036015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Neuroprotective effects of fingolimod in mouse models of Parkinson&#x02019;s disease</article-title><source>FASEB J</source><year>2017</year><volume>31</volume><issue>1</issue><fpage>172</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1096/fj.201600751r</pub-id><pub-id pub-id-type="pmid">27671228</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Zhao P, Yang X, Yang L, Li M, Wood K, Liu Q, et al. Neuroprotective effects of fingolimod in mouse models of Parkinson&#x02019;s disease. FASEB J. 2017;31(1):172&#x02013;9.<pub-id pub-id-type="pmid">27671228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Asle-Rousta</surname><given-names>M</given-names></name><name><surname>Oryan</surname><given-names>S</given-names></name><name><surname>Ahmadiani</surname><given-names>A</given-names></name><name><surname>Rahnema</surname><given-names>M</given-names></name></person-group><article-title>Activation of sphingosine 1-phosphate receptor-1 by SEW2871 improves cognitive function in Alzheimer&#x02019;s disease model rats</article-title><source>Excli j</source><year>2013</year><volume>12</volume><fpage>449</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">26417237</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Asle-Rousta M, Oryan S, Ahmadiani A, Rahnema M. Activation of sphingosine 1-phosphate receptor-1 by SEW2871 improves cognitive function in Alzheimer&#x02019;s disease model rats. Excli j. 2013;12:449&#x02013;61.<pub-id pub-id-type="pmid">26417237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Beider</surname><given-names>K</given-names></name><name><surname>Rosenberg</surname><given-names>E</given-names></name><name><surname>Bitner</surname><given-names>H</given-names></name><name><surname>Shimoni</surname><given-names>A</given-names></name><name><surname>Leiba</surname><given-names>M</given-names></name><name><surname>Koren-Michowitz</surname><given-names>M</given-names></name><etal/></person-group><article-title>The Sphingosine-1-Phosphate modulator FTY720 targets multiple myeloma via the CXCR4/CXCL12 pathway</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><issue>7</issue><fpage>1733</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2618</pub-id><pub-id pub-id-type="pmid">27697999</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Beider K, Rosenberg E, Bitner H, Shimoni A, Leiba M, Koren-Michowitz M, et al. The Sphingosine-1-Phosphate modulator FTY720 targets multiple myeloma via the CXCR4/CXCL12 pathway. Clin Cancer Res. 2017;23(7):1733&#x02013;47.<pub-id pub-id-type="pmid">27697999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><mixed-citation publication-type="other">Guo X-D, Ji J, Xue T-F, Sun Y-Q, Guo R-B, Cheng H et al. FTY720 exerts Anti-glioma effects by regulating the Glioma Microenvironment through increased CXCR4 internalization by Glioma-Associated Microglia. Front Immunol. 2020;11:178.</mixed-citation></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Gualtierotti</surname><given-names>R</given-names></name><name><surname>Guarnaccia</surname><given-names>L</given-names></name><name><surname>Beretta</surname><given-names>M</given-names></name><name><surname>Navone</surname><given-names>SE</given-names></name><name><surname>Campanella</surname><given-names>R</given-names></name><name><surname>Riboni</surname><given-names>L</given-names></name><etal/></person-group><article-title>Modulation of Neuroinflammation in the Central Nervous System: role of chemokines and sphingolipids</article-title><source>Adv Therapy</source><year>2017</year><volume>34</volume><issue>2</issue><fpage>396</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1007/s12325-016-0474-7</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Gualtierotti R, Guarnaccia L, Beretta M, Navone SE, Campanella R, Riboni L, et al. Modulation of Neuroinflammation in the Central Nervous System: role of chemokines and sphingolipids. Adv Therapy. 2017;34(2):396&#x02013;420.</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Harun</surname><given-names>N</given-names></name><name><surname>Thien</surname><given-names>M</given-names></name><name><surname>Juarez</surname><given-names>JG</given-names></name><name><surname>Bradstock</surname><given-names>KF</given-names></name><name><surname>Bendall</surname><given-names>LJ</given-names></name></person-group><article-title>S1P1 agonists for Use as Adjunct Mobilizing agents</article-title><source>Blood</source><year>2010</year><volume>116</volume><issue>21</issue><fpage>826</fpage><pub-id pub-id-type="doi">10.1182/blood.V116.21.826.826</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Harun N, Thien M, Juarez JG, Bradstock KF, Bendall LJ. S1P1 agonists for Use as Adjunct Mobilizing agents. Blood. 2010;116(21):826.</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Saito-Reis</surname><given-names>CA</given-names></name><name><surname>Balise</surname><given-names>VD</given-names></name><name><surname>Pascetti</surname><given-names>EM</given-names></name><name><surname>Jiminez</surname><given-names>M</given-names></name><name><surname>Gillette</surname><given-names>JM</given-names></name></person-group><article-title>Tetraspanin CD82 regulates S1PR1-mediated hematopoietic stem and progenitor cell mobilization</article-title><source>Stem Cell Rep</source><year>2021</year><volume>16</volume><issue>10</issue><fpage>2422</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2021.08.009</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Saito-Reis CA, Balise VD, Pascetti EM, Jiminez M, Gillette JM. Tetraspanin CD82 regulates S1PR1-mediated hematopoietic stem and progenitor cell mobilization. Stem Cell Rep. 2021;16(10):2422&#x02013;31.</mixed-citation></citation-alternatives></ref></ref-list></back></article>